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I. Summary  
A very special connective tissue surrounds and interweaves solid tumors, the tumor stroma. 
Initially thought to only have a passive role, there is now more and more evidence 
accumulating that the tumor stroma plays an active function in the process of tumor 
progression as well as tumor initiation. Activated stromal cells express pro-proliferative 
paracrine signals to the epithelial cells, stimulate angiogenesis and can even show loss of 
tumor suppressor genes. Therefore, understanding the complex crosstalk between the 
epithelium and the tumor stroma might reveal novel therapeutic targets. Tenascin-C is known 
to be specifically expressed in the stroma of a variety of tumors triggering different stromal 
reactions required for tumorigenesis such as angiogenesis. We found in the stroma of mouse 
mammary tumors the induction of a second member of the tenascin family, tenascin-W. 
Moreover, we detected human tenascin-W in different human neoplasms, and could correlate 
its expression in breast cancers with tumor grade. Tenascin-W is enriched in low-grade breast 
cancers whereas the presence of tenascin-C does not correlate with tumor grade. Functionally, 
we could show that presence of tenascin-W does influence the cellular behavior of cancer 
cells. Fibroblasts adhere on tenascin-W in a β1-integrin-dependent way, and cancer cell 
migration towards fibronectin is stimulated by addition of tenascin-W. 
 
In order to evaluate the significance of tenascin-W to act as tumor marker, we established a 
sensitive sandwich-ELISA to measure serum tenascin-W levels. By screening sera of healthy 
volunteers and sera from cancer patients, we could detect elevated serum tenascin-W levels in 
non-metastatic colorectal and non-metastatic breast cancer patients. However, not all cancer 
patients did show this increase. Furthermore, we found high tenascin-W expression in a large 
fraction of colorectal cancer extracts, but complete absence in normal colon mucosae. This 
suggests that tenascin-W is a better tumor marker for colorectal cancer than tenascin-C, which 
is also expressed in the normal colon mucosa. These observations warrant a follow-up study 
to evaluate the potential diagnostic or prognostic relevance of tenascin-W in colorectal cancer.  
 
Glioblastomas are very aggressive human cancers. We found that glioblastomas frequently 
harbor amplifications at the Notch2 locus and express high levels of Notch2 protein, which 
coincided with the presence of tenascin-C, an established prognostic marker for 
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glioblastomas. A conserved potential RBPJk binding motif was found in the tenascin-C 
promoter sequence, and by luciferase assays we could identify tenascin-C as a new RBPJk-
dependent Notch-2 target. Furthermore, we could induce endogenous tenascin-C by 
transfecting fibroblasts with the intracellular Notch2 domain. These data imply a novel 
oncogenic function of Notch2 by inducing tenascin-C, a molecule enhancing cancer cell 
motility.   
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II. Introduction 
Formation and maintenance of multicellular structures requires a supporting framework to 
hold cells together. On the one hand, this is achieved by cell-cell junctions, which directly 
link neighboring epithelial cells and in addition to mechanical attachment serve many more 
purposes, such as force transmission to the cytoskeleton and generation of cell shape and 
polarity [1]. On the other hand, an essential part of the supporting framework is supplied by 
the extracellular matrix (ECM), a complex network of proteins which cells secrete and 
organize around themselves (Fig.II.1A). In the past the ECM was simply viewed as passive 
component functioning as inert scaffolding to stabilize the physical structure of tissues. 
During the last couple of years, however, it has become evident that the ECM is a very active 
and dynamic structure: it is subject to constant renewal; it has architectural roles during 
development and tissue repair; it regulates all the important cellular processes such as cell 
proliferation, differentiation, apoptosis, adhesion, and migration; it provides positional and 
environmental information essential for tissue maintenance and function; it harbors growth 
factors or growth factor-binding proteins, therefore playing an active role in their 
mobilization. Finally, there is strong evidence of its importance during a diversity of diseases, 
including cancer. The development and normal functioning of multicellular organisms 
depends on constant communication and interactions with molecules in the environment, 
including growth factors, cell adhesion molecules and various components of the ECM (for 
reviews see [2-4]). Therefore, careful analysis of the structure and function of specific 
components of different ECMs is a very important prerequisite to understand the molecular 
mechanisms of tissue interactions. 
 
Connective and epithelial tissues represent two extremes of organization (Fig.II.1B). 
Polarized epithelial cells are tightly bound together via specialized cell junctions forming the 
epithelial sheets which line all surfaces and the internal cavities of the body. Underlying the 
basal surface of epithelial cells, there is a thin but dense layer of ECM, known as the 
basement membrane (BM) (Fig.II.1C/D). Its major functions include the separation of 
epithelial tissue from the interstitial matrix and the provision of adhesive sites for integrins 
expressed on epithelial cells thereby giving epithelial cells a polarized structure. The BM is 
assembled from proteins secreted largely by the epithelial cells. The main components include 
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type IV collagen, laminins, perlecan and nidogen [5]. In contrast to the BM in epithelial 
tissues, the ECM in connective tissue, which often carries mechanical load, takes up a large 
volume and the cells that produce this matrix, mainly fibroblasts, are sparsely distributed 
within it (Fig.II.1). 
 
     A        B 
 
 
 
 
 
 
 
 
     C                   D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. 1: Epithelial and connective tissue 
(A) Scanning electron micrograph shows fibroblasts embedded into a complex meshwork of proteins which they 
secrete and organize around themselves [6]. (B) Schematic representation of the epithelial cell sheet which is 
separated from the connective tissue by the basement lamina. Taken from [7]. (C) Scanning electron micrograph 
of a chick corneal epithelium. The basement membrane (BM) separates the epithelial cells (Ep) from the 
underlying connective tissue, which is composed of stromal cells and a network of collagen fibers (C). (D) 
Epithelium of a mouse trachea viewed at higher magnification through a transmission electron microscope. 
Epithelial cells (Ep) are located above the BM, while below are collagen fibrils (C), a fibroblast (F), and elastin 
fibers (E). The BM stays intact at the intercellular space (IS). Pictures (B) and (C) are taken from [8]. 
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There is a considerable variation in the composition and amount of the ECM produced in 
different tissues, leading to an astonishing diversity in their physical properties: e.g. the BM 
in kidneys serving as a filtration barrier, resilient ECM of tendons, the cushioning, shock-
absorbing ECM of cartilage in our joints, and the mineralized matrix of bones and teeth.   
 
Essentially, there are three main classes of proteins that make up the ECM in mammals: (i) 
fibrous collagens, (ii) proteoglycans, and (iii) glycoproteins. Collagens, the most abundant 
proteins in mammals, form long triple-stranded helical structures and are packed together into 
thick fibers which provide tensile strength. Other collagens (e.g. type XII collagen), do not 
form fibrils, but associate with them and link them to one another and to other ECM 
components. Proteoglycans (e.g. aggrecan) are proteins to which different negatively charged 
polysaccharide chains, called glycosaminoglycans (GAGs), are covalently attached, thereby 
creating highly charged structures. This negative charge attracts osmoticly active cations 
leading to the recruitment of water. As a consequence, a swelling pressure is produced 
enabling the matrix to withstand compression (e.g. in cartilage). Glycoproteins (e.g. 
fibronectin, laminins, tenascins) fulfill cross-linking functions to other ECM molecules or to 
cells by means of their multiple binding domains.  
 
To sum up, in order for each organ to successfully fulfill its characteristic functions within a 
given organism, all cells must be integrated into a framework which gives them structural and 
signaling input. Cells must know their exact position and environment and they must be able 
to send out and receive the correct signals at the right time and place. If successful, this leads 
to tissue homeostasis. Failures in generating homeostasis result in a wide spectrum of 
dysfunctions, including cancers. The focus of the first part of the introduction is on tumor 
development and progression with an emphasis on the tumor microenvironment rather than on 
the cancer cell itself. Thereafter, the tenascins, a family of ECM proteins, are introduced, 
which are well recognized to play an important role in the development of organisms as well 
as in different pathological situations [9]. 
INTRODUCTION 
 
 
10 
II.1 Tumors and their microenvironment 
Conventional knowledge states that carcinogenesis is a multistep process that reflects the 
acquisition and accumulation of mutations or epigenetic changes leading to genetic alterations 
(reviewed in [10-12]). In their landmark review, Hanahan and Weinberg (2000) enumerated 
six traits, probably shared by all types of human tumors that collectively dictate malignant 
growth. However, the order in which these capabilities are reached seems to be variable. 
These capabilities are (i) self-sufficiency in growth signals, (ii) insensitivity to anti-growth 
signals, (iii) resistance to apoptosis, (iv) limitless replicative potential, (v) sustained 
angiogenesis, and (vi) acquisition of properties required for tissue invasion and metastasis. 
Generally, there are three critical gene classes whose alterations are responsible for tumor 
progression: oncogenes, tumor suppressors, and caretaker (stability) genes. Mutations in 
oncogenes lead to the activation (or even to a constitutive activation) of the gene in conditions 
where the wild-type gene is normally not active. Such activation can arise from intragenic 
mutations, chromosomal translocations or gene amplifications. On the other hand, tumor 
suppressor genes show a reduced activity when altered, which renders them insufficient in 
counter-balancing the “growth-promoting” genes. Epigenetic silencing, miss-sense mutations, 
deletions or insertions can cause inactivation of these genes. Unlike oncogenes, tumor 
suppressors follow the “two-hit hypothesis” [13], which implies that both the maternal and 
paternal allele have to be mutated to manifest the phenotype. Genes that ensure the repair of 
subtle mistakes that may occur during DNA replication, belong to the class of caretakers or 
stability genes. Their function is to keep the general mutation rate in a cell to a minimum. As 
a consequence, mutations in caretaker genes result in an increased mutation rate, rendering 
oncogenes and tumor suppressors more prone to deleterious mutations. 
 
A large amount of effort has been invested in the discovery and molecular analysis of genes 
belonging to any of these classes and the signaling pathways cancer cells are abusing for 
malignant growth (Fig.II.2). Research was clearly focused on the cancer cell itself and has 
resulted in considerable advances of our knowledge underlying the basic mechanisms for 
tumor formation and cancer therapies. However, recently it has become apparent that tumors 
are not just accumulations of carcinoma cells but represent very complex systems [14, 15]. In 
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carcinomas (solid, epithelial cell-derived tumors), neoplastic epithelial cells coexist with the 
surrounding connective tissue, the so-called tumor stroma which is composed of various cell 
types and is rich in ECM. During tumorigenesis, stromal components create a complex, 
tumor-permissive microenvironment that neoplasms require for their full manifestation [16, 
17]. For a long time, it was believed that the tumor stroma only plays a passive role in the 
development of a tumor, even though the contribution of the microenvironment to tumor 
progression was already postulated in 1889 by Stephen Paget’s “seed and soil” hypothesis 
[18]. By analyzing 735 cases of breast cancer, he found that metastases formed in the liver far 
more often than in any other organ. Hence, he proposed that breast tumor cells (seeds), 
although transported throughout the vasculature, only can live and grow where they find a 
permissive environment (soil). 
 
 
Figure II. 2: Signaling pathways within a cell 
Emergent picture of the complex signaling pathways within a cell is shown. Genes that are known to be altered 
in cancer are highlighted in red [12]. 
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As mentioned earlier, the stromal microenvironment is composed of a complex framework 
including a specific type of ECM, the tumor matrix, as well as several cell types such as those 
that are able to respond to inflammation (lymphocytes, macrophages, mast cells), those which 
are important for the vasculature (endothelial cells, pericytes, smooth muscle cells), and 
fibroblasts, which are the main producer of the ECM. The amount of stroma and its 
composition varies greatly from tumor to tumor, but does not correlate with the degree of 
malignancy. Nevertheless, it has become clear that each cell type present in the tumor stroma 
can have a variable influence upon tumor progression depending on tumor type (for reviews 
see [14, 16, 17, 19-23]).  
II.1.1 The normal microenvironment acts as a tumor suppressor  
The function of the stromal microenvironment under physiological conditions is to generate 
and maintain tissue homeostasis. Proper tissue architecture is established by the BM, a 
specialized matrix separating the epithelial cells from stromal cells, thereby suppressing 
inappropriate mixing of cells from different tissue types. Recently, the general notion about 
the BM has changed from simply being a structural barrier to represent a much more dynamic 
structure influencing cellular behavior. Therefore, the BM provides structural support and acts 
as a signaling substratum to orient cells through integrin-based adhesions, and it determines 
cellular apical and basal surfaces to the epithelium (reviewed in [5]). Proper signaling and 
communication with the surrounding ECM and neighboring cells keeps the cells constrained 
within one tissue compartment. Overall, the normal stromal microenvironment provides 
essential signals for a structured, differentiated epithelial phenotype as well as for proper 
adhesions (Fig.II.3A). In early-stage tumors, it can even act as a non-permissive barrier to 
block or delay tumorigenesis. For instance it was shown that disorganization and disruption of 
the periglandular BM and hemidesmosome structures in breast tissue correlates with 
malignant phenotype [24]. In Drosophila, loss of epithelial polarity induced by the absence of 
a protein called scribble, triggers neoplastic transformation [25, 26]. Therefore, it is 
hypothesized that as long as proper tissue architecture can be maintained, it is very difficult 
for a cancer cells to overcome this constraint [15]. Thus, an intact microenvironment has the 
capability to act as a powerful tumor suppressor, even in the presence of transformed 
epithelial cells. This tumor-suppressing property of the microenvironment was already 
INTRODUCTION 
 
 
13 
postulated a long time ago [27]. Subcutaneous injection of embryonal carcinoma cells into 
mice resulted in the formation of teratocarcinomas. In contrast, the same cancer cells injected 
into a blastocyst gave rise to phenotypical normal chimeric mice, indicating that, although 
pre-disposed to malignancy, the blastocyst environment might have acted as a tumor 
suppressor and kept the malignancy in check [27]. 
 
 
A          B       C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. 3: Transition from the normal to the reactive stroma 
(A) The well-differentiated epithelium is separated by a BM from the underlying stromal compartment, which 
includes ECM proteins, fibroblasts, endothelial cells and leukocytes. (B) Pre-malignant dysplasia in the 
epithelium results in disturbed tissue homeostasis. Although the BM remains intact, fibroblasts are activated and 
stromal changes occur. (C) Cross-talk between the epithelium and the stroma through soluble effector molecules 
leads to secretion of proteolytic enzymes resulting in the breakdown of the BM, the differentiation of activated 
fibroblasts to myofibroblasts, and to ECM remodeling, thereby forming a congenial tumor microenvironment 
[16]. 
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II.1.2 Activation of the stroma 
Cancer cells possess the ability to alter their adjacent stroma to form a tumor permissive 
environment, called activated or primed stroma [14, 16, 17, 20, 23]. Therefore, it is not 
surprising that during the transition of a normal epithelium to pre-malignant conditions 
stromal changes occur, which have been initiated by soluble tumor cell-derived factors 
(Fig.II.3B). Initially, the BM remains intact, still separating the two compartments, one 
consisting of neoplastic epithelial cells and the other of stromal cells. However, cancer cells 
start to produce and secrete factors such as basic fibroblast growh factors (bFGF), vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth 
factor (EGF), transforming growth factor beta (TGFβ) or hepatocyte growth factor (HGF). 
These factors act alone or in concert to stimulate both stromal and tumor cells as paracrine 
and autocrine signals. Consequently, these factors trigger the induction of stromal reactions, 
including angiogenesis [28], inflammatory responses [21, 22], or activation of fibroblasts 
[19], finally leading to a congenial stroma for tumors.  
 
Activation of fibroblasts eventually leads to their differentiation into myofibroblasts 
(Fig.II.3C) or so-called cancer-associated fibroblasts (CAFs). They possess highly increased 
contractibility and they produce smooth muscle α-actin which makes them distinguishable 
from normal fibroblasts (Fig.II.4A) [19]. CAFs start producing specific ECM components 
such as SPARC (secreted protein acidic and rich in cysteine), fibronectin containing an extra 
domain a, and tenascin-C. These proteins are usually not expressed or only to a limited 
amount under physiological conditions. Tenascin-C for instance influences many different 
stromal reactions including angiogenesis, immune and inflammatory responses and it 
provides oncogenic signals to the cancer cells leading to changes in their behavior (reviewed 
in [9] and see chapter II.2.3.1 “Tenascin-C and cancer”). Furthermore, CAFs secrete growth 
factors, among them the tumor-growth promoting and angiogenesis enhancing stromal-cell-
derived factor 1 (SDF1) [29, 30], which acts by direct paracrine stimulation via the CXCR4 
receptor expressed on carcinoma cells and on endothelial precursor cells (EPCs) [30]. Finally, 
CAFs produce cytokines, serine proteases and matrix metalloproteinases (MMPs), which 
mediate processes such as ECM remodeling, activation of the inflammatory response, and 
INTRODUCTION 
 
 
15 
stimulation of tumor angiogenesis by attracting EPCs. As a consequence, a congenial tumor 
microenvironment is formed, which facilitates tumor progression (Fig.II.4B). Activity of 
proteolytic enzymes leads to the breakdown of the BM and to the mixing of the cells from the 
epithelial compartment with stromal cells, and to the degradation of stromal ECM proteins. 
Thus the sustained presence of CAFs and other activated stromal cells in the tumor stroma has 
harmful consequences for tissue homeostasis, ultimately leading to an environment which 
enables tumor cell migration and invasion [19].  
 
 
 
 
 
 
 
 
 
  B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. 4: Cancer-associated fibroblasts 
(A) By acquiring an activated phenotype (right), fibroblasts alter their genetic program and their 
microenvironment. (B) Activated fibroblasts influence different stromal reactions through soluble growth 
factors, cytokines, chemokines or ECM molecules such as tenascins [19]. 
A
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Accompanying or preceding the stromal changes, cancer cells alter their morphology from a 
well-differentiated to a migratory and invasive phenotype. During this process of epithelial-
mesenchymal transition (EMT), cells downregulate their epithelial-specific tight and adherens 
junction proteins and start expressing mesenchymal molecules instead. As a result, cells lose 
their cell-cell contacts which is required for cell invasion and motility (for reviews see [31-
33]). 
 
Normal stromal cells can acquire activated phenotypes also under non-tumorigenic conditions 
by various stimuli that arise when tissue injury occurs, when the tissue architecture is 
disrupted or in events of acute inflammation. Under these non-tumorigenic conditions, there is 
a discrete order of events. Usually, the injured epithelial cells are the source of the chemical 
signals that trigger and maintain a host response with the goal to heal the damaged tissue. 
These factors include the pro-inflammatory cytokines, tumor necrosis factor α (TNFα) or 
TGFβ1. As a consequence, resident mast cells, macrophages and dendritic cells are activated 
and recruited to the site of tissue damage. As a second step there is infiltration of effector 
immune cells (lymphocytes) which are responsible for specific immune responses. Once these 
cells are activated, they immediately release soluble mediators such as cytokines, chemokines, 
proteases and reactive oxygen species (ROS), which activate and recruit endothelial and 
mesenchymal cells to sites of tissue injury to form new blood vessels and collagen matrices 
(Fig.II.5A) (reviewed in [21, 22, 34]). 
 
This process of stroma activation is successfully mimicked by cancer cells resulting in a 
striking histological and mechanistical similarity between an activated tumor stroma and the 
healing wound environment (Fig.II.5B). Moreover, epidemiological data indicate that more 
than 15% of human malignancies arise in association with chronic inflammation, viral or 
bacterial infections [21], which further highlights the contribution of the activated stroma to 
tumor progression. For example, helicobacter pylori infection has been linked to gastric 
cancer, hepatitis B virus to hepatocellular carcinoma, and chronic pancreatitis to pancreatic 
carcinomas [22]. However there are major differences between a non-cancerous activated 
stroma and the activated tumor stroma. In a healing wound, the activated state of the involved 
cells is reverted once the repair is completed. During carcinogenesis, however, the events 
occurring in the process of a healing wound become chaotically disorganized. The regulatory 
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mechanisms to revert the activated cell state back to normal are lost leading to the sustained 
presence of activated stromal cells. Therefore, a concept of tumors as “wounds that do not 
heal” was postulated [35]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. 5: Similarities between inflammation and cancer 
(A) Tissue injury leads to a discrete order of events: (i) activation of resident cells, (ii) infiltration of effector 
immune cells, (iii) activation and mobilization of endothelial cells and fibroblasts leading to the formation of 
new blood vessels and collagen matrices. (B) In cancer, the same events are disorganized and homeostasis is not 
achieved [36]. 
A B 
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A large amount of attention is paid to CAFs and their contribution to cancer progression and 
initiation (reviewed in [19]). However, not much is known about the nature of the CAF’s, 
their origin, and what distinguishes them from the normal fibroblasts. It is clear that CAF’s 
are not identical to fibroblasts of normal adjacent tissue [37]. Unlike their normal counterparts 
which only marginally contribute to tumor growth [29], CAFs contain tumor-promoting 
properties. This was shown by comparing CAFs extracted from several human prostate 
carcinomas to normal fibroblasts isolated from non cancerous prostate gland. When mixed 
with non-tumorigenic human prostate epithelial cells and injected into immunodeficient host 
mice, only CAFs were able to stimulate the growth of the tumor mass [38]. Furthermore 
CAFs express proteins typical for fibroblasts (e.g. SDF-1 and FSP1), but also α-smooth 
muscle actin resembling myofibroblasts. Thus, they could be derived from fibroblasts, 
fibroblast-precursor cells, vascular smooth muscle cells or from carcinoma cells via EMT 
[39]. 
II.1.3 Activated stromal cells as new therapeutic targets 
A major question remains: is the miss-function of the epithelium preceding the dysfunction of 
the stroma or vice versa? Although it was thought for a long time that the initial inductive 
trigger to drive tumor formation was provided by transformed epithelial cells, there is now 
increasing evidence that the stroma can have a more direct role in the progression of a tumor. 
A genetically unstable stroma might further increase the instability of the epithelium and 
therefore might act as a mutagen. In particular, stromal fibroblasts are thought to be potential 
inducers of certain carcinomas [19]. They directly influence the epithelium-mesenchyme 
cross-talk and epithelium transformation by secreting paracrine factors affecting normal 
epithelial cells as well as cancerous cells [19]. In addition, several unique chromosomal 
rearrangements were specifically found in stromal cells by PCR analysis of DNA extracts 
from stromal and epithelial tissues of mammary ductal carcinomas [40]. This implies that 
genetic alterations in stromal cells might occur without, or at least precede abnormalities in 
the epithelial cells. Furthermore, cells of the stromal compartment can even show loss of 
tumor suppressor genes [41]. Experiments using irradiation of stromal cells provided further 
evidence for an active role of these cells in cancer initiation and progression [42]. Injection of 
non-transformed mammary epithelial cells into irradiated cleared fat pads resulted in an 
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increase of breast tumor incidence compared with injections of similar epithelial cells in to fat 
pads containing non-irradiated fibroblasts. [42]. Senescent fibroblasts, which express similar 
sets of growth factors as CAFs, can also promote growth of epithelial cells in vitro and in vivo 
[43]. More recently the effect of TGFβ signaling in stromal cells was elucidated by 
conditionally knocking out the TGFβ type II receptor gene in fibroblasts [44]. This study 
showed that loss of the TGFβ pathway in fibroblasts stimulates growth and cancerogenesis of 
adjacent epithelia, which is probably due to dysfunctions in the HGF signaling pathway [45]. 
In summary there is now a lot of data suggesting that the activated stroma not only supports 
cancer progression, but also might play an active role in the initiation of a cancer by acting as 
a mutagen or by harboring mutations in tumor suppressor genes. Clearly, modifications of 
stromal fibroblasts can influence the malignant phenotype of adjacent epithelia (reviewed in 
[19]) .  
 
All of these findings lead to a re-evaluation of the role of the tumor stroma in cancer initiation 
and progression and allows new strategies for cancer prevention and intervention (for reviews 
see [16, 36]). Normalization of an aberrant microenvironment could have the potential to 
reverse the tumorigenic phenotype or at least slow down tumor progression, even though the 
epithelial cells retain all their mutations. New strategies could include (i) removal or 
neutralization of the cancer-promoting features of CAFs by targeting specific cell surface 
marker of CAFs, for instance FSP-1 [46], which is not present in normal somatic tissues; (ii) 
prevention of tumor angiogenesis by blocking pro-angiogenic effector molecules or using 
anti-angiogenic molecules such as endostatin or tumstatin which are generated by proteolysis 
of collagen and other BM molecules (reviewed in [5]); or (iii) targeting mechanisms of 
tumoral immune tolerance or chronic inflammation which predisposes patients to cancer 
(reviewed in [47]). Hence, the activated stroma offers a lot of therapeutic targets, including 
activated cells, soluble effector molecules such as proteases or factors involved in the 
interaction between the epithelial and mesenchymal compartment. Beneficially and in contrast 
to cancer cells, stromal cells are generally more genetically stable and are therefore thought 
less likely to become resistant to therapy.  
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In summary, it is now well accepted that tumor progression needs malignant cells as well as 
an appropriate microenvironment and that it requires an extensive cross-talk between these 
two key components. This cross-talk leads to the recruitment of host cells and to their 
activation, which triggers pro-survival, proliferation and invasion pathways in both the cancer 
cells and their host (Fig.II.6) [48]. Full understanding of the defects in communication 
between malignant epithelial cells and host stromal cells could generate new promising 
targets for cancer treatment. Therefore, novel approaches for cancer therapy are being 
developed to target the oncogenic functions of the tumor stroma. A promising approach in 
treating cancers probably consists of a combination of conventional drugs, which target the 
highly proliferative cancer cell and anti-stromal agents, including enzyme and protease 
inhibitors (e.g. MMPs inhibitors), anti-adhesive molecules such as anti-integrin peptides or 
antibodies, signal modulators, and anti-fibrotic drugs. Ultimately, more information about the 
complex molecular and cellular cross-talk between the epithelium and the mesenchyme will 
lead to a better understanding of tumor development and progression and hence, should result 
in novel successful strategies for treatment or prevention of cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II. 6: Cross-talk between tumor cells and activated stromal cells 
Tumor cells activate and change their microenvironment by secreting growth factors and proteases, which can 
act in autocrine and paracrine manners to the tumor cells and/or to the stroma. Basically, all the activated stromal 
cells contribute to tumor progression [16]. 
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II.2 Tenascins 
The tenascins are a highly conserved family of large oligomeric glycoproteins present in 
many ECM’s throughout the body (for reviews see [9, 49-51]). Whereas no tenascins have 
been identified in the Caenorhabditis elegans genome or in arthropod genomes, vertebrate 
genomes harbor four tenascin genes, which have been termed tenascin-C (TN-C), tenascin-R 
(TN-R), tenascin-X (TN-X), and tenascin-W (TN-W). ECM proteins such as tenascins are 
present during the development of an organism as well as in several different pathological 
situations, including tissue remodeling processes, inflammation and tumorigenesis [9, 52]. 
However, the functional impact of their presence is not very well understood so far. 
Nevertheless, it is suggested that tenascins act through interactions with specific cell surface 
receptors [49] as well as through binding to and blocking essential sites on other ECM 
molecules [53], thereby changing cellular behavior and signaling. 
 
Although each tenascin family member has a very distinct expression pattern and shows 
discrete functional features, they share the characteristics of being tightly regulated during 
development and in the adult organism. Furthermore, they are all built from a common set of 
structural motifs, a typical feature of ECM proteins [54], in the same linear arrangement: 
amino-terminal heptad repeats, epidermal growth factor (EGF)-like repeats with the 
consensus sequence X4CX3CX5CX4CXCX8C, fibronectin type III (FN III) domains, and a 
carboxyl-terminal globular domain shared with fibrinogens (Fig.II.7A). At their amino-
terminus, each tenascin contains an oligomerization domain allowing the formation of 
trimeric structures and in the case of TN-C and TN-W to the formation of hexamers, so-called 
hexabrachions [55, 56], by the assembly of two trimers (Fig.II.7B). However, there is great 
variance in number and nature of EGF-like repeats and FN III domains between the different 
members of the tenascin family and also within specific tenascin orthologs [57]. Alternative 
splicing within the stretch of FN III domains has been described for TN-C and TN-R 
(Fig.II.7A). But only TN-C splice variants have been shown to be significantly expressed in 
specific tissues and to have distinct functions [9, 58-64]. 
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Figure II. 7: The tenascin family 
(A) Schematic representation of one subunit of each of the four tenascin members. The following symbols have 
been used to identify the structural domains: heptad repeats (wavy line), EGF-like repeats (diamonds), constant 
fibronectin type III domains (grey boxes), fibronectin type III domains subject to alternative splicing (black 
boxes), fibrinogen globe (circle). (B) Electron micrograph of a tenascin-C and tenascin-W molecule after rotary 
shadowing shows their hexameric structure. Pictures are taken from [9, 56]. 
II.2.1 Tenascin-R 
TN-R is predominantly expressed in the central nervous system (CNS) by oligodendrocytes 
[65], although there has been one report published showing TN-R expression in a peripheral 
nervous sytem-derived cell line [66]. Typical TN-R subunits consist of 4.5 EGF-like repeats 
and 8-9 FN III domains. Alternative splicing leads to two isoforms, however, their functional 
significance is not well understood so far [67, 68]. During the development of the CNS, TN-R 
expression shows partial overlap with TN-C, although TN-R appears at later time points. In 
vitro and in vivo studies have shown that TN-R on one hand induces actin-rich processes and 
branches along neurite shafts [69], promotes neuronal cell adhesion and migration, and on the 
other hand acts as a repellent guidance molecules for axons [70, 71]. TN-R knock-out mice 
are viable and fertile, and brain areas known to express TN-R in wild-type mice seem 
apparently normal [72]. Only recently, more detailed investigations revealed behavioral 
defects such as compromised motor coordination, decreased willingness to explore or 
increased anxiety in TN-R knock-out mice [72-74]. 
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II.2.2 Tenascin-X 
TN-X was identified as a “gene X” located in the major histocompatibility complex (MHC) 
class III gene locus [75]. Containing 18.5 EGF-like repeats and 32 FN III domains (human) it 
is the largest member of the tenascin family. A unique feature of TN-X is the interruption of 
the FN III domains by a proline-rich stretch of about 100 amino acids. It is widely expressed 
during development, but is limited to the connective tissue of heart and skeletal muscle as 
well as to the dermis of skin in the adult [76, 77]. In vitro studies revealed that TN-X mediates 
cell adhesion, but not cell spreading [78]. TN-X is the first tenascin whose deficiency has 
been clearly connected to a pathological syndrome in humans, the Ehler-Danlos Syndrome 
(EDS). TN-X is located in a group with the genes RP, C4 and it overlaps in opposite direction 
with a gene called CYP21 [79], the gene coding for steroid 21-hydroxylase, whose deletion 
results in congenital adrenal hyperplasia (CAH) [79]. This genetic unit occurs in tandemly 
repeated fashion, which makes it prone to numerous recombination events leading to diverse 
genetic diseases [80, 81]. First cases of human TN-X deficiencies were found in patients 
suffering from clinical signs of both CAH and EDS indicating a deletion of CYP21 extending 
to the TN-X gene. EDS patients show symptoms which can be linked to ECM structural 
defects. They include poor wound healing, skin and joint hyper extensibility. These classical 
symptoms are caused by defects in collagen structure or collagen-processing enzymes. This 
implies a function of TN-X in either collagen fibril deposition into the ECM or regulation of 
the spacing between fibrils. Thereby, TN-X contributes to elasticity and strength of the dermis 
[82-84]. One possibility to achieve this would be through direct binding of TN-X to collagen 
fibrils, or to fibril-associated collagens such as collagen XII. Several lines of evidence 
strongly support the physical interaction between TN-X and collagens [85, 86]. 
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II.2.3 Tenascin-C 
TN-C is the founding member of the tenascin family. More than two decades ago, it was 
discovered as an ECM protein enriched in the stroma of gliomas [87] and as a myotendinous 
antigen [88]. Mammalian TN-C proteins normally contain 14.5 EGF-like repeats and 8 
constant FN III domains, whereas 9 additional FN III domains can be included in a 
combinatorial manner by alternative splicing. This results in a great number and diversity in 
isoforms [89]. A prominent feature of TN-C is the assembly into hexamers, so-called 
hexabrachions (Fig.II.6B) [55].  
 
TN-C together with proteins such as TN-X, SPARC, osteonectin, osteopontin, 
thrombospondin-1 and thrombospondin-2 belong to a class of extracellular matrix proteins 
which have been termed matricellular proteins [90, 91]. Matricellular proteins are defined by 
modulating cell-matrix interactions and cell function rather than having a direct structural 
role. TN-C expression is high during embryogenesis, but almost absent during normal 
postnatal life with some basal expression detectable in tendons and ligaments only. In adult 
life, TN-C is also expressed within the sub-ventricular zone (SVZ) in the CNS, a region that 
constitutes the neural stem cell niche [92]. A prominent feature of TN-C is its re-appearance 
in response to pathological situations such as infection, inflammation and tissue remodeling 
processes [93]. Another striking example of a pathological situation leading to the sharp re-
expression of TN-C is the onset of tumorigenesis, where TN-C is specifically expressed in the 
activated tumor stroma [9].  
 
Due to its prominent expression in tendons and embryonic ECMs, the gene family was named 
tenascin, which comes from tenere (to hold) and nasci (to be born) [94]. For most cells, TN-C 
does not support cell spreading and is therefore called anti-adhesive. Several receptors (e.g. 
intergrins α2β1, αvβ3 and α9β1, annexin II, and syndecan) and interactors (e.g. perlecan, 
fibronectin) have been described for TN-C which might account for the different effects 
attributed to TN-C (for a review see [95]). However, the finding that TN-C knock-out mice 
showed grossly normal phenotypes challenged the idea of TN-C as an important or essential 
protein which was assumed due to its highly regulated expression and its well conserved 
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presence in vertebrate genomes, both at DNA and protein levels [96]. However, more careful 
studies analyzing these mice revealed subtle abnormalities in behavior, wound healing, airway 
branching and angiogenesis [96-99]. 
II.2.3.1 Tenascin-C and cancer 
TN-C is strongly expressed in the stroma of various cancers and has been reported to be 
associated with the invasive front of the tumors (for review see [100]). For cancers in the 
lung, colon, and brain, high TN-C expression correlates with poor prognosis, whereas in other 
cancer no clear correlation between TN-C and survival or malignancy exists [95]. Why this 
correlation applies to certain tumors only is not understood yet, but may reflect the fact that 
TN-C might have specific functions in different tumors. Some studies revealed the presence 
of specific TN-C isoforms in tumors, making it possible to get a more precise interpretation of 
the tumor physiology according to isoform expression [9, 59, 101-103]. In search for new 
diagnostic or prognostic tumor markers, TN-C levels have often been analyzed in sera of 
cancer patients and its potential value as a biomarker has been evaluated [104-108]. Although 
elevated TN-C serum levels have been found in certain cancers, it still remains a questionable 
tumor marker [104]. TN-C levels are scattered over a wide range with many cancer patients 
having normal TN-C concentrations and its expression strongly correlates with inflammation 
or infection [9]. 
 
TN-C can be induced by various stimuli: first, there are the pro- and anti-inflammatory 
cytokines such as different interleukins, TNFα or IFNγ and secondly, there are growth factors 
such as TGFβ, EGF or PDGF that are secreted either by transformed epithelial cells or by 
activated stromal cells [9, 109-111]. Furthermore, TN-C inducing stimuli include mechanical 
stress [112, 113], hypoxia [114, 115], and reactive oxygen species [116], factors or conditions 
which also might play a prominent role in tumors. It is astonishing that TN-C expression is 
very tightly regulated during development and in the adult organism despite this wide range 
of TN-C inducers. 
  
By now it seems clear that TN-C is an ECM protein having anti-adhesive properties for cells 
when offered as substratum. Active inhibition of cell spreading by TN-C was further 
confirmed by mixing TN-C together with fibronectin, which is a classical adhesion protein 
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[117]. Whereas on fibronectin cells nicely spread, form focal contacts and actin stress fibers 
(Fig.II.8A), the same cells plated on a mixed fibronectin-TN-C substratum are not able to 
spread and do not form focal contacts and actin cables (Fig.II.8B).  
 
A             B 
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Figure II. 8: Tenascin-C inhibits cell spreading on fibronectin 
(A) T98G glioblastoma cells plated on fibronectin form nice actin stress fibers and focal adhesions (arrowhead) 
as revealed by phalloidin and vinculin staining. (B) T98G cells plated on fibronectin/TN-C fail to form actin 
stress fibers and focal adhesions and keep a roundish morphology [53]. 
 
 
 
The molecular mechanism for this TN-C interference with fibronectin-mediated cancer cell 
spreading was only recently elucidated (Fig.II.9A/B) [53]. Cell spreading on fibronectin 
involves the classical fibronectin receptor integrin α5β1 in synergy with the transmembrane 
heparin sulfate proteoglycan syndecan-4 [118]. TN-C was shown to bind to the 13th FN III 
domain of fibronectin which is located within the heparin binding site II serving as ligand for 
syndecan-4. As a consequence of this competitive binding, the interaction of cells with 
fibronectin through syndecan-4 is prevented leading to the inhibition of cell spreading [53]. 
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To find molecular changes in cells induced by TN-C, RNA profiling of glioblastoma cells 
revealed that presence of TN-C activates oncogenic signaling pathways such as EGFR [119], 
ERK/MAPK, and Wnt (Fig.II.9C) [120].  
 
 
   A       C 
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Figure II. 9: Model of tenascin-C action 
(A) Full cell spreading on fibronectin needs integrin α5β1 and syndecan-4 binding. The synergistic binding 
activates Rho signaling, leading to the formation of stress fibers and cell spreading. (B) TN-C interferes with 
syndecan-4 binding to fibronectin, thereby disturbing the synergy between integrin α5β1 and syndecan-4. As a 
consequence, Rho is not activated anymore, actin stress fibers are disassembled and cell spreading is abolished. 
(C) Presence of TN-C with fibronectin leads to the activation of Wnt signaling by downregulation of DKK1, a 
Wnt inhibitor. On the other hand, TN-C mixed with fibronectin inhibits FAK, Rho and tropomyosin-1 (TM1) 
causing cell rounding. Pictures (A) and (B) were taken from [9], picture (C) from [95]. 
 
 
Overall, we can conclude that TN-C is a prominent ECM protein specifically expressed in the 
tumor stroma by activated stromal fibroblasts (see chapter II.1.2 “Activation of the stroma”). 
It influences several stromal reactions which are implicated in the progression of tumors. 
Similar to normal tissues, tumors reaching a certain size require an adequate supply of 
oxygen. Therefore, the process of tumor angiogenesis is essential for the expansion of a tumor 
mass [121, 122]. There is increasing evidence that TN-C is involved in this crucial process. 
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On one hand it was shown that TN-C is expressed around angiogenic vessels in many tumors 
[123-126] and on the other hand, it promotes and regulates angiogenesis in vitro and in vivo 
[97, 127]. Moreover, in glioma patients, clinical studies revealed an inhibition of tumor 
angiogenesis by applying antibodies directed against TN-C [128]. 
 
Tumor promoting activities of TN-C further include promotion of cancer cell proliferation 
[120], and enhanced glioma cell invasiveness in a 3-D collagen I matrix by up-regulating 
MMP-12 [129]. Furthermore, TN-C is part of the gene expression signature that identifies 
metastatic breast cancer cells preferentially metastasizing to the lung [130]. These 
observations imply a tumor promoting and oncogenic role for TN-C [100, 120, 129, 131, 
132]. Since several molecules with demonstrated functions in maintaining genome stability 
and genome integrity were down-regulated in the presence of TN-C [120], it was 
hypothesized that TN-C might also influence genome stability, a further factor that can 
facilitate tumor formation (for review see [100]). TN-C expression in the neural stem cell 
niche [92, 133] as well as the observation that TN-C is important for stem cell number 
maintenance [134] may define a novel link to tumorigenesis. The recent realization that 
cancers may rely on cancer stem cells [135, 136] is supporting this hypothesis. 
 
The question now is how to exploit this knowledge about TN-C expression and function in 
tumors for the benefit of patients. So far the only approach in cancer therapy involving TN-C 
is the use of monoclonal antibodies specific to TN-C. In glioblastoma and lymphoma patients 
radiolabeled antibodies specific to TN-C have been successfully used in the clinic for the 
treatment of these patients [137-139]. The aim of this method is to deliver therapeutic 
radionuclides or other bioactive molecules very specifically to the tumor site, which is rich in 
TN-C, using conjugated anti-tenascin monoclonal antibodies. This strategy allows a very 
local administration of the drug thereby preventing damage of the neighboring healthy tissue. 
This approach may interfere with tumor progression of glioblastomas and may even result in 
tumor regression [128, 140]. 
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II.2.4 Tenascin-W 
TN-W is the newest, and the last member of the tenascin family. It was initially identified in a 
screen for tenascin-related molecules by screening a zebrafish cDNA library constructed 20-
28 hours after fertilization for the EGF-like repeats conserved in all tenascins [141]. Zebrafish 
TN-W contains 3.5 EGF-like repeats, followed by 5 FN III domains. The expression pattern 
was investigated by in situ hybridization in embryos and juvenile zebrafish. TN-W was found 
to be expressed in migrating cells of sclerotomal and neural crest origin partially overlapping 
with TN-C expression [141]. More recently, TN-W was identified and characterized in the 
mouse [56]. Similar to TN-C, electron microscopy after rotary shadowing of the purified TN-
W showed the formation of hexamers (Fig.II.7B). Immunohistochemistry revealed prominent 
expression in the developing and adult metanephric kidney, developing and adult bones and 
transient expression in smooth muscles of the developing gut, often but not always 
overlapping with TN-C expression [56]. Another report of murine TN-W, referred to as 
tenascin-N [142], claims its expression in developing and adult brain. However, these 
findings could not be confirmed by others. Functional studies indicate that TN-W is an 
adhesive substratum for C2C12 cells and that their adhesion to TN-W is α8β1-integrin 
dependent. Furthermore, it was shown that TN-W expression can be induced in C2C12 cells 
by bone morphogenetic protein 2 (BMP-2) [56]. A gene and a putative human cDNA for TN-
W have been annotated in the DNA databases (accession number # AL049689).  
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II.3 Aim of the work 
The primary goal of this work was to characterize human TN-W by studying its expression 
pattern in different human tumors and to elucidate its biological function. To reach that aim, 
tools had to be generated, such as recombinant TN-W protein for functional studies and 
antibodies for the detection of TN-W in cells, tissues, and serum samples. The diagnostic or 
prognostic value of measuring serum TN-W levels was assessed by screening human sera 
from healthy volunteers and from tumor patients. As a side project, tools (antibodies, 
recombinant protein) for studying chicken TN-W functions during development were 
prepared as well. 
 
Finally, I also focused on new aspects of TN-C presence in different human pathologies. 
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III. Results  
III.1 Published papers 
III.1.1 Tenascin-W is found in malignant mammary tumors, promotes 
alpha8 integrin-dependent motility and requires p38MAPK activity 
for BMP-2 and TNF-alpha induced expression in vitro 
 
Arnaud Scherberich, Richard P.Tucker, Martin Degen, Marianne Brown-Luedi, Anne-
Catherine Andres and Ruth Chiquet-Ehrismann 
 
Oncogene, 2005, 24: 1525-32 
 
 
 
My contribution: I studied the effect of α8-integrin expression on cell adhesion and cell 
migration of 3T3 cells on a murine tenascin-W substratum. 
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III.1.2 Avian tenascin-W: expression in smooth muscle and bone, and 
effects on calvarial cell spreading and adhesion in vitro  
 
 
Caroline V Meloty-Kapella, Martin Degen, Ruth Chiquet-Ehrismann and Richard P Tucker 
 
Developmental Dynamics, 2006, 235: 1532-1542 
 
 
 
 
My contribution: cloning and sequencing of full-length chicken tenascin-W cDNA; 
expression and purification of chicken tenascin-W; production of the polyclonal anti chicken 
tenascin-W antibody  
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Abstract 
Tenascins are extracellular matrix proteins present during the development of organisms as 
well as in pathological conditions. Tenascin-W, the fourth and last member of the tenascin 
family remains the least well-characterized one. Our study aimed to evaluate the potential 
significance of tenascin–W as cancer biomarker by monitoring its presence in the serum of 
colorectal and breast cancer patients and its expression in colorectal tumor tissues. To 
measure serum tenascin-W levels, a sensitive sandwich-ELISA was established. Mean 
tenascin-W concentration in sera of patients with non-metastatic colorectal cancer at time of 
diagnosis was highly increased compared to that of healthy volunteers. A similar tendency 
was observed for tenascin-C in the same patient cohort. However, the increase was much 
more striking for tenascin-W. We also detected elevated tenascin-W levels in sera of breast 
cancer patients. Furthermore, we could show a prominent expression of tenascin-W in 
extracts from colorectal tumor tissues by immunoblot analysis, whereas tenascin-W was not 
detectable in the corresponding normal colon mucosa. To confirm the western blot results, we 
performed immunohistochemistry of frozen sections of the same patients as well as of an 
additional, independently chosen collection of colorectal cancer tissues. In all cases, similarly 
to tenascin-C, tenascin-W was detected in the tumor stroma. Our results reveal a clear 
association between elevated levels of tenascin-W and the presence of cancer. These results 
warrant further studies to evaluate the potential value of serum and tissue tenascin-W levels as 
diagnostic, prognostic or monitoring biomarker in colorectal, breast and possibly other solid 
cancers. 
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Introduction 
Tumor development and progression is not only dependent on the acquisition and 
accumulation of mutations leading to genetic alterations in cancer cells (for reviews see 1, 2), 
but in addition depends on the cross-talk between the transformed epithelium and the tumor 
stroma, consisting of various cell types (e.g. activated fibroblasts, angiogenic endothelial 
cells, infiltrating inflammatory cells) and modified extracellular matrix (ECM) 3, 4. In recent 
years it has been recognized that cancer cells are able to alter and activate their adjacent 
stroma by secreting soluble factors promoting the formation of a growth-permissive 
microenvironment required for full neoplastic manifestation 5-7. 
The adhesion-modulating ECM molecule tenascin-C is expressed de novo by activated 
fibroblasts in most solid tumors 7-9. Tumor promoting activities of tenascin-C include 
abolishment of cancer cell spreading on fibronectin through blocking of syndecan-4 10, 11, 
promotion of cancer cell proliferation 10, induction of angiogenesis 12, and enhanced cell 
invasiveness by up-regulating MMP-12 13. Moreover, tenascin-C can trigger oncogenic 
signaling pathways such as EGFR 14, 15, ERK/MAPK and Wnt 16. Importantly, tenascin-C is 
part of the gene expression signature that identifies metastatic breast cancer cells 
preferentially metastasizing to the lung 17. Since tenascin-C is absent or expressed at greatly 
reduced levels in the adult organism, but gets re-expressed in tumors 18, it was reasonable to 
assume that increased tenascin-C expression in most cancers may be reflected in elevated 
tenascin-C levels in body fluids. Indeed, elevated levels of tenascin-C have been reported in 
serum of patients with different cancer types, including glioma, prostate or colorectal 
carcinomas, metatstatic melanoma, squamous cell carcinoma of head and neck, and non-small 
cell lung cancer 19-25. However, the values for tenascin-C in serum of cancer patients were 
scattered over a wide range and a significant fraction of these patients had normal 
concentrations, resulting in a low sensitivity of tenascin-C measurement for detecting cancers. 
Moreover, high serum tenascin-C levels were clearly correlated with non-cancerous liver 
diseases including hepatitis and liver cirrhosis 26-29, and with elevated levels of C-reactive 
protein (CRP) 21, an acute phase protein expressed as a consequence of infection, tissue 
damage or other inflammatory conditions 30, 31. 
Tenascin-W was originally identified in zebrafish where it was shown to be co-expressed with 
tenascin-C by neural crest cells and in somites 32. More recently, murine 33 and chicken 34 
tenascin-W have been described and in both of these animals tenascin-W was expressed in 
RESULTS - PUBLISHED 
 
69 
 
developing and adult smooth muscle cells and bone. Chicken tenascin-W function includes 
modulation of calvarial cell adhesion and spreading in vitro 34. So far only little is known 
about tenascin-W expression in cancer. The first study linking tenascin-W expression to the 
presence of a tumor was performed in mice. Using oncogene-induced mammary tumor 
models, it was shown that tenascin-W is highly expressed in the tumor stroma sharing its 
prominent expression with tenascin-C 35. Functional studies identified mouse tenascin-W as a 
molecule promoting migration of mammary cancer cells 35. Recently, we confirmed the 
presence of tenascin-W in the stroma of human breast cancer tissues 36. 
Since little is known yet about human tenascin-W expression in health and disease, we 
decided to study its presence in serum of patients with colorectal or breast cancer and 
investigated its presence in tumor tissues.  
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Materials and Methods 
Recombinant proteins 
Human tenascin-W and tenascin-C were cloned, expressed and purified as described 
previously 36, 37. Fibronectin was purified from filter-sterilized horse serum using a gelatin-
agarose column. After washing of the column with PBS, fibronectin was eluted with 4 M 
Urea and finally dialyzed against PBS. Human fibrinogen was purchased from Sigma (Sigma, 
Buchs, Switzerland). 
 
Anti-tenascin-W antibody production 
Two polyclonal antisera recognizing human tenascin-W were generated. The first antiserum, 
called pAb (FL), was raised in rabbits against the purified full-length human tenascin-W 36 
(Fig. 1a, indicated by the long line). To raise the second polyclonal antisera in rabbits, a 
recombinant fragment of human tenascin-W was cloned, bacterially expressed, and purified. 
To clone the recombinant fragment, specific primers were designed to amplify the sequence 
encoding the last two fibronectin type III domains with the Expand High Fidelity PCR System 
(Roche, Rotkreuz, Switzerland). The cDNA of the full-length human tenascin-W (described 
above) was used as template and the PCR was performed with the primer set 5’-
GAGGATCCGAAATTGACGGCCCCAAAAACC-3’/5’-
ATAAGCTTATGTGGAGAGGGTGGTGGA-3’. The forward primer included a BamHI 
restriction site and the reverse primer a stop codon immediately followed by a HindIII 
restriction site to enable the directional cloning into the bacterial expression vector pQE30 
(Qiagen, Hilden, Germany), supplying a C-terminal His tag for the purification of the 
recombinant fragment. The recombinant fragment corresponding to fibronectin type III 
domains 3F/4 (Fig. 1a, short line below the molecule) was expressed and purified by affinity 
chromatography to a Ni-NTA matrix (Qiagen, Hilden, Germany) following the supplier’s 
instructions. Purification was performed under native conditions and elution by 250 mM 
imidazole (pH 6.9). The bacterially expressed fragment of tenascin-W was then used to raise 
polyclonal antisera (pAb (3F/4)) in rabbits using standard immunization procedures. 
 
To raise monoclonal antibodies (mAbs) in mice, a recombinant fragment of human tenascin-
W containing the last three fibronectin type III domains (Fig. 1a, short line above the 
molecule) was cloned, bacterially expressed, and purified as described above. To clone the 
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recombinant fragment, cDNA was synthesized from total RNA that was extracted from Saos-
2 cells (ATCC # HTB-85) by TrizolTM reagent (Invitrogen, Carlsbad, CA, USA). Primers 
amplifying the last three FN type III domains, were used for nested PCR with the Expand 
High Fidelity System (Roche, Rotkreuz, Switzerland) using the Saos-2 cDNA as template. 
The first reaction was performed with the primer set 5’-
GGGAAGGAGCAGAGTAGCACTG-3’ / 5’-CCGCCTCTGGAAGACAATCC-3’, the 
second reaction with the primers 5’-AGGGATCCGACATTGACAGCCCCCAAAACC-3’ / 
5’-CTAAGCTTTCATGTGGAGAGGGTGGTGGATAC-3’. The forward primer for the 
second PCR included a BamHI restriction site and the reverse primer a stop codon 
immediately followed by a HindIII restriction site to enable the directional cloning into the 
bacterial expression vector pQE30 (Qiagen, Hilden, Germany), supplying a C-terminal His 
tag for the purification of the recombinant fragment. MAbs were obtained by immunizing 
female BALB/c mice with 34.6 µg of the purified recombinant tenascin-W fragment 
emulsified with STIMUNE (ID-Lelystad, Institute for Animal Sciences and Health, Lelystad, 
NL). For boosting, mice were injected twice with a 4-week interval with 25 µg tenascin-W 
fragment. Splenic lymphocytes were fused with the myeloma cell line P3X63Ag8.653 (ATTC 
# CRL-1580) and cultured according to standard protocols. The hybridoma supernatants were 
analyzed by ELISA and western blot analysis of a tenascin-W fragment expressed in HEK293 
cells using a construct containing the sequence of the last three FN III domains of tenascin-W 
fused to an N-terminal fragment of chicken tenascin-C containing its secretion signal and the 
epitope for the well characterized anti-chicken tenascin-C antibody mAb 60 38. IgGs from two 
mAb hybridoma clones (mAb 29A and mAb 56O) were purified from conditioned medium by 
protein G sepharose (Amersham, Otelfingen, CH) and used in this study. 
 
Sandwich-ELISA 
Immunolon 1 flat-bottomed 96-well plates (Dynatech Laboratories, Chantilly, VA, USA) 
were coated with 50 µl of mAb 29A (capture antibody, 10 µg/ml in PBS) for 1 hour at 37°C 
and blocked with 4 % milk in PBS (blocking and washing solution) for another hour at room 
temperature. After washing the plate twice, 50 µl of serum samples or standard (purified 
human tenascin-W), both diluted in blocking solution, were incubated for 1 hour at 37°C. 
Each serum was assayed in a 2-fold dilution series ranging from 1:2 to 1:8. Samples were 
discarded and the plates were washed extensively four times with washing buffer. After 
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incubation with 50 µl of pAb (FL) (detection antibody, 1:500 in blocking solution, 1 hour at 
37°C), the plates were washed again four times and incubated with peroxidase-labeled goat 
anti-rabbit IgG (1:2000 in blocking solution, 1 hour at 37°C). After washing the plates four 
times with washing buffer and twice with PBS, the enzymatic color reaction was carried out 
by adding 100 µl of reaction buffer (0.1 M citric acid, 0.2 M Na2HPO4, 4 mM 1, 2-
phenylendiamine, 0.003 % H2O2). The reaction was stopped with 50 µl of 4 M H2SO4 and the 
plates were read with a VERSAMAX Microplate reader (Molecular Devices, Sunnyvale, CA, 
USA) at 490 nm against 620 nm. 
 
To monitor serum tenascin-C, sandwich-ELISAs were performed as described previously 21 
using the anti-human tenascin-C mAb B28.13  as capture antibody, a polyclonal chicken anti-
human tenascin-C as detection antibody (1:500) and a peroxidase-labeled goat anti-chicken 
IgG (1:15,000), and with purified human tenascin-C as standard. 
 
Patient population and serum preparation 
Patients were between the age of 48 and 94 years (average age 70.3 years), presenting non-
metastatic colorectal cancer (CRC) and scheduled for tumor resection. Exclusion criteria 
included patients with less than 10 g/dl hemoglobin, leucopenia, thrombocytopenia, deep 
venous thrombosis during the last three months, long term vascular catheter, chronic vascular 
or inflammatory disease, surgery and chemotherapy during the last 4 and 6 months 
respectively.  
 
Healthy volunteers were gender mixed and between 30 and 76 years old, without history of 
cancer, chronic disease or medication other than hormonal contraception. Although the 
average age of 43 was lower than that of the cancer patients, there was no indication of an 
increase of tenascin-W levels with age.  Ethical and scientific approvals were given by the 
local Ethics Committee of the Lausanne University Hospital. Written informed consent was 
obtained from all the patients and healthy volunteers.  
 
For serum preparation, blood was collected in tubes without anticoagulant. After a 10 minute 
centrifugation at 1,000g, the serum was extracted and frozen at -80° C until use. 
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Histological diagnosis and grade of all tumors was reviewed by one pathologist (SW) 
according to the WHO Classification of Tumors 39. Tumor stage was determined using the 
International Union Against Cancer (TNM classification of malignant tumors) 40. 
 
Human tissue extracts and western blot analysis 
Fresh human tissue was frozen on dry ice immediately after surgery. For the processing of the 
tissue, it was thawed on ice, minced and homogenized in lysis buffer (100 mM phosphate 
buffer pH 8.0, 300 mM NaCl, 8 M Urea, 1 % Triton-X-100, 10 mM beta-mercaptoethanol, 50 
mM Guanidium Hydrochloride and complete protease inhibitor cocktail (Roche, Rotkreuz, 
Switzerland)). Insoluble material was pelleted and reducing SDS-PAGE sample buffer was 
added to the supernatant and boiled for 5 minutes at 95°C. After electrophoresis on 6 % 
polyacrylamide gels, proteins were electro-transferred onto polyvinyldifluoride membrane 
(Millipore, Bedford, MA, USA) using a semi-dry blotting apparatus (Millipore, Bedford, MA, 
USA). After the transfer, membranes were stained with amido black to control equal protein 
loading. After blocking for 1 hour at room temperature in TBS containing 0.05 % Tween and 
5 % skim milk powder, membranes were incubated overnight with either the polyclonal 
tenascin-W  antiserum (pAb (3F/4); 1:750), the mAb 56O raised against tenascin-W (1:1000), 
the mAb B28-13 raised against tenascin-C (1:100) 21, or the mAb against vinculin (1:2000; 
Sigma, Buchs, Switzerland) followed by an incubation for 1 hour with anti-rabbit IgG or anti-
mouse IgG coupled to horseradish peroxidase (1:10,000), respectively. Blots were developed 
using Super Signal (Pierce, Rockford, IL, USA) and exposed to Kodak BioMax MR Films. 
 
Immunohistochemistry and Frozen Tissue Microarray 
A frozen tissue microarray (TMA) was constructed from frozen tissue samples of 32 colon 
carcinoma and 6 normal colon mucosae.  Pathological features of these samples are 
summarized in Table III (patients 1-38). The TMA was constructed in frozen Tissue-Tek 
OCT compound (Miles Laboratories, Naperville, IL, USA) as described previously 41. We 
optimized a commercial microarray device (Beecher Instruments, Sun Prairie, WI, USA) by 
using a 0.6 mm drill for recipient whole making instead of the conventional hollow needle. 
All immunostainings were performed using the Discovery XT automated stainer (Ventana 
Medical Systems, Tucson, AZ, USA), with DAB Map detection kit (Ventana). Frozen tissue 
slides were dried for 1 hour at room temperature, fixed for 10 minutes at 4°C in acetone and 
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then introduced into the automate. No pretreatment was required for any staining. Slides were 
first blocked twice for 12 minutes with the AB Block reagent (Ventana). Then they were 
incubated for 1 hour at 37°C with mAb B28-13 against tenascin-C (1:2500), and mAb 56O 
against tenascin-W (1:800). Afterwards, slides were treated for 32 minutes at 37°C with a 
biotinylated universal secondary antibody (Ventana) and counterstained with hematoxylin and 
bluing reagent (Ventana). 
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Results 
Precision and sensitivity of the sandwich-ELISA 
Serum tenascin-W levels were analyzed by a sandwich-ELISA using mAb 29A as capture 
antibody and pAb (FL) as detection antibody (Fig. 1a). Specificity of the detection antibody 
was assessed by western blot analysis of tenascin-W conditioned medium, purified 
fibronectin, fibrinogen, tenascin-C, and tenascin-W (Fig. 1b). The anti-tenascin-W antiserum 
pAb (FL) specifically reacts with the human tenascin-W conditioned medium and with the 
purified tenascin-W, but did not show any cross-reactivity with tenascin-C or any of the other 
related proteins tested, which are known to be present in serum (Fig. 1b). 
 
To further rule out that our detection antibody recognizes serum contaminants potentially 
binding to tenascin-W we used two distinct polyclonal anti-human tenascin-W antibodies pAb 
(FL) and pAb (3F/4) for tenascin-W detection. Table Ia shows that both polyclonal detection 
antibodies measure similar tenascin-W concentrations in the same serum samples making it 
highly unlikely that they cross-react with contaminating serum proteins possibly bound to 
tenascin-W. Furthermore, pAb (FL) recognizes different epitopes of tenascin-W than pAb 
(3F/4) since, in contrast to pAb (3F/4), its reactivity with tenascin-W can not be blocked by 
the addition of the bacterial expressed fragment used to raise pAb (3F/4) (Fig. 1c). 
 
Testing a serial dilution of our purified tenascin-W, we concluded that with our newly 
established sandwich-ELISA, serum tenascin-W concentrations as low as 0.005 mg/l could be 
detected. A typical standard curve for tenascin-W is shown as log-log presentation in Figure 
1d. When we tested a different capture antibody (mAb 56O) we obtained the same results as 
with mAb 29A (data not shown) and decided to use mAb 29A for all further sandwich-
ELISAs. The precision of the assay was estimated by testing 4 serum samples three times in 
one assay (“within-run”, Table Ib) or in duplicates in two consecutive assays (“between-run”, 
Table Ic). The coefficient of variation (CV) was 5.6 +/- 1.3 % in the within-run and 6.52 +/- 
4.9 % in the between-run. Therefore, we have established a sensitive, specific and precise 
sandwich-ELISA to detect tenascin-W in human serum samples.   
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Tenascin-W is up-regulated in the serum of colorectal and breast cancer patients 
Since tenascin-C was shown to be elevated in serum samples of colorectal cancer patients 20, 
25, we were interested to test whether tenascin-W shares this property with tenascin-C. 
Therefore, we measured tenascin-W levels in serum of 17 non-metastatic (at time of 
diagnosis) colorectal cancer patients and compared it to the levels monitored in the serum of 
25 healthy volunteers. The mean value of tenascin-W in the control sera was 0.389 +/- 0.14 
mg/l (Fig. 2a). This is about half of the published mean serum tenascin-C level in healthy 
individuals 21, 42. Serum tenascin-W concentrations in colorectal cancer patients were 
significantly elevated compared to those in healthy individuals (p < 0.01) with a mean level of 
0.794 +/- 0.38 mg/l (Fig. 2a). This corresponds to a 2-fold increase in comparison to healthy 
volunteers. Immunoprecipitation (IP) followed by immunoblot analysis of serum samples 
resulted in the detection of a single tenascin-W-specific band, corresponding to the size of the 
purified full-length tenascin-W (data not shown). This indicated that we were measuring 
intact mature tenascin-W protein in the serum. We also assayed the same sera for tenascin-C 
and obtained a mean tenascin-C level in healthy volunteers of 0.775 +/- 0.25 mg/l (Fig. 2b), 
which nicely matches the range described in the literature 21, 42. The mean tenascin-C value in 
colorectal cancer sera was 0.98 +/- 0.24 mg/l and corresponds to a 1.2 fold increase compared 
to control sera (Fig. 2b). Clinicopathologic features of the colorectal cancer patients available 
for our study as well as their individually measured tenascin-W and tenascin-C levels are 
given in Table II. Although both tenascins showed the same tendency of increased levels in 
colorectal cancer patients, the difference in the mean value in cancer sera compared to 
volunteers was much more pronounced for tenascin-W. However, not every patient with a 
high tenascin-C serum level also contained high levels of tenascin-W (Table II), indicating 
that there is no strict correlation between serum levels of the two tenascins in colorectal 
cancer patients.Although, there was no overt correlation between elevated serum tenascin-W 
levels and staging of the colorectal tumors, it is worth noting that 4 out of 5 patients who 
developed tumor recurrence after surgery had high levels of tenascin-W. Mean serum 
tenascin-W level of recurrent patients (n=5) was 1.02 +/- 0.34 mg/l which corresponds to a 
1.5-fold increase compared to non-recurrent colorectal cancer patients (n=12, mean=0.700 +/- 
0.37 mg/l) and a 2.6-fold increase compared to healthy volunteers (Table II).  
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To test whether tenascin-W might be a specific serum marker for colorectal cancers or 
whether tenascin-W might have a broader spectrum of application, we analyzed tenascin-W in 
serum of 16 non-metastatic (at time of diagnosis) breast cancer patients and compared it to the 
levels monitored in healthy volunteers. The mean serum value of tenascin-W in the breast 
cancer cohort was 0.682 +/- 0.43 mg/l. This corresponds to a statistically significant (p<0.02) 
1.75-fold increase compared to healthy volunteers (Fig. 2c). From these data we conclude that 
serum levels of tenascin-W are elevated in non-metastatic breast and colon cancer patients at 
time of first curative-intent surgery compared to healthy individulas. 
 
Tenascin-W expression in normal colon and cancer tissue 
To determine whether increased expression of tenascin-W in the tumor tissue could explain 
the elevated serum levels in colorectal cancer patients, we performed immunoblots on 11 
colorectal tumor tissue extracts. As shown in Figure 3a, a large fraction of the tumor tissue 
samples contained detectable levels of tenascin-C (9/11; 82%). Furthermore, tenascin-W was 
also highly expressed in these tumor extracts (9/11; 82%). In two cases (patients E and F) 
tenascin-W and tenascin-C were absent or barely detectable while all other samples tested 
showed co-expression of the two tenascins (Fig. 3a). Besides tumor tissue, corresponding 
normal mucosa was available for patients K and L, and for patient J we obtained normal tissue 
only. In all normal colon mucosae tested, tenascin-W was not detectable even though the 
tumor tissue extracts of the same patients revealed strong tenascin-W expression (patients K 
and L). This is in contrast to tenascin-C which was also detectable in normal colon mucosae, 
but at a much reduced level compared to the corresponding tumor sample. For tenascin-C, we 
detected different isoforms, whereas for tenascin-W we mostly observed a single band in the 
extracts tested. However, there was a faint second lower tenascin-W band detectable in tumor 
extracts of patients B and I. This smaller band is likely to represent degradation products of 
tenascin-W, but we cannot exclude that it might be due to a low level of alternative splicing. 
Tenascin-C isoform expression differed between tumor and normal tissues. In normal colon 
mucosae, only the low molecular-weight isoform could be observed, whereas in tumor 
extracts low and high molecular-weight isoforms were detectable. In summary, the majority 
of human colorectal tumors express both tenascins, but their relative amount varies greatly 
between patients.  
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In order to confirm expression of tenascin-W and tenascin-C in tumor tissues and to localize 
their presence within the tissues, we stained frozen sections of normal colon mucosa and 
tumor tissue of patients K and L by immunohistochemistry. The staining pattern was the same 
for both patients. As shown for patient L (Fig. 3b) tenascin-C as well as tenascin-W staining 
revealed a very strong expression in the tumor stroma, the specialized connective tissue 
surrounding cancer cells. The normal colon mucosa was positive for tenascin-C but not 
tenascin-W consistent with the immunoblot findings. The tenascin-C expression was strong in 
the muscularis mucosa and was also present surrounding the glands. Taken together, 
immunohistochemical staining of frozen sections confirmed the result obtained by 
immunoblotting of the same colorectal tumor extracts and indicated that tenascin-W is a novel 
marker for activated tumor stroma in colorectal cancer.   
 
To extend this analysis to a larger number of samples we stained a frozen colon tissue micro 
array (TMA) that contained 32 cancer spots and 6 spots of normal colon. Without exception 
all cancer tissue sections were stained for tenascin-W as well as tenascin-C, while all normal 
tissues were negative for tenascin-W, but positive for tenascin-C (Table III). Examples of the 
different staining patterns observed are shown in Fig. 4. Most of the tenascin-C positivity in 
normal colon tissue is seen in smooth muscle (Fig. 4, patient 36). In some of the tumors 
tenascin-W and tenascin-C stainings seemed to overlap entirely (Fig. 4, patients 4, 5), whereas 
in others the tenascin-W positive areas were a subset of the tenascin-C positive region (Fig. 4, 
patient 12). As can be observed in Fig. 4 (patient 15) the tenascin-C positive and tenascin-W 
negative area in tumors may also be due to the presence of smooth muscle, as can be seen at 
the boarder of a tumor and normal tissue (Fig. 4, patient 26). The extent of staining always 
overlapped with the stromal compartment of the tumor as judged from the H&E stained 
sections (Fig.4). In Table III patient data are summarized and the staining patterns are 
classified according to the area of the staining observed. This shows that tenascin-C has a 
slightly broader distribution than tenascin-W. Since tenascin-C is strongly expressed in 
smooth muscle of the colon, this may reflect the presence of smooth muscle cells within the 
cancer stroma. 
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Discussion 
In 2006, colorectal cancer was the second major cause of cancer deaths in Europe, 
accountable for 207,400 deaths (12.2 % of total cancer deaths) 43. Colorectal carcinomas 
develop in defined stages over several years 44. Deaths from colorectal cancer may be 
prevented inmost cases if the tumor is detected at an early stage (polyp or non-invasive 
carcinoma) and removed by endoscopic polypectomy or surgery. In this context, effective 
screening tools are of utmost importance. Because of the low accuracy and sensitivity of the 
classical fecal occult blood test, several biochemical markers have been developed and 
explored over the years for colorectal cancer screening, including carcinoembryonic antigen 
(CEA) serum levels 45, galactose-N acetylgalactosamine fecal levels 46, and K-Ras mutations 
in human stool 47, 48 , but none is enough sensitive and specific for early cancer detection. 
Recently, the tumor M2-Pyruvate kinase, a dimeric form of the enzyme that catalyzes the last 
reaction within the glycolytic pathway was found to be up-regulated in both plasma and fecal 
samples of patients suffering from gastrointestinal cancers, including colorectal cancers 49-53. 
Nevertheless, the most effective available method to prevent and detect colorectal cancer 
today is colonoscopy. However, this investigation is invasive, time-consuming, 
uncomfortable, and relatively expensive 54. Moreover, the frequency of the colonoscopic 
exams every 3 to 5 years is limited by these factors and it is not rare to observe the 
development of cancer between two colonoscopies. Thus surrogate markers of colon cancer 
detectable in the blood may be a convenient method for screening and early cancer detection..  
In search for new diagnostic or prognostic tumor markers, tenascin-C levels have often been 
analyzed in sera of cancer patients and its potential value as a biomarker has been evaluated 
21-23, 55, 56. Although elevated tenascin-C serum levels have been found in certain cancers, it 
still remains a questionable tumor marker 21. Its levels are scattered over a wide range with 
many cancer patients having normal tenascin-C concentrations and its expression strongly 
correlates with sites of inflammation or infection 18.  
 
In this report we evaluate tenascin-W for its potential to serve as biomarker in colorectal 
cancer. A sensitive, precise and tenascin-W-specific sandwich-ELISA was established using 
different anti-tenascin-W antibodies and the purified protein as a standard. We were able to 
detect and measure tenascin-W in the serum of healthy volunteers and colorectal cancer 
patients. The mean serum tenascin-W level in healthy individuals was 0.389 +/- 0.145 mg/l. 
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Homogeneously low levels in a control population is a strict requirement for a cancer 
biomarker. In comparison, serum levels of tenascin-C in controls were 2-fold higher and 
scattered over a broad range. Interestingly, we observed a clear increase in mean tenascin-W 
levels in colorectal cancer sera (0.794 +/- 0.38 mg/l). The histogram in Figure 2a (right), 
however, shows that within the cohort of the colorectal cancer patients, there are two 
subpopulations: one with elevated tenascin-W levels (approximately 2.5 times the mean of 
control values), the other with levels comparable to the controls. We could not identify any 
simple correlation between clinicopathologic features of the tumors, patients’ characteristics 
and any of these patient groups. The meaning and relevance of these two subpopulations is 
not clear at this point. One plausible explanation is that not all tumors lead to an elevation of 
tenascin-W in serum due to differences in their cell biology or accompanying events (e.g. 
stromal reaction). Alternatively these groups may represent different kinetics of tenascin-W 
elevation in serum, whereby ‘normal’ levels would become elevated later during disease 
progression. Another important issue is whether the level of tenascin-W is associated with 
more unfavorable disease progression. In this regard, it is noteworthy that the follow-up 
studies of the colorectal cancer patients revealed that 4 out of 5 patients who developed tumor 
recurrence after treatment had high tenascin-W levels (i.e. above mean levels) in their sera 
(Table II). This suggests a potential value of tenascin-W levels in sera in predicting recurrence 
or progression, but the limited size of the patient cohort analyzed in this initial study is too 
small to draw any conclusions at this point. A study addressing this question is planned.  
It is also important to consider that the presence of tenascin-W, or of any other biomarker in 
serum, could be influenced by any co-morbidity (e.g. cardiovascular diseases, inflammatory 
disease) or through indirect effects of the tumor on other organs (e.g. bone marrow, liver). For 
instance tenascin-C serum levels were shown to correlate with inflammation rather than 
tumorigenesis 21, but so far no correlation could be found linking tenascin-W to the presence 
of infection or inflammation (own unpublished observations).  
 
We confirmed the tendency of tenascin-C to be present at higher levels in the serum of 
colorectal cancer patients (0.98 +/- 0.24 mg/l), however, the increase was much more 
moderate than for tenascin-W. We neither could observe a correlation between the levels of 
the two tenascins, nor with the classification and staging of the primary tumor. We also 
monitored a clear increase (1.75-fold) in the mean serum tenascin-W level in non-metastatic 
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breast cancer patients compared to that in healthy individuals. This indicates that tenascin-W 
is not a biomarker specific for adenocarcinomas of the colon, but might have a broader 
spectrum for possible applications. More studies are necessary to fully appreciate the 
expression of tenascin-W in different cancers. 
 
To test for expression of tenascin-W in the tumor, we investigated tumor extracts of 11 
colorectal cancer patients and for some of them, corresponding normal tissue by 
immunoblotting. We could show that tenascin-W as well as tenascin-C was detectable in the 
tumor tissue in 82 % of the patients. Since the immunoblotting analysis of tumor tissue was 
performed on different colorectal cancer patients we cannot make direct correlations between 
local tenascin-W expression in the tumor and corresponding circulating levels in the serum. 
Tenascin-W, however, was absent from normal colon mucosa, in contrast to tenascin-C, 
which is expressed (at reduced levels) in the normal tissue as well. Interestingly, in the normal 
tissue, only the low molecular-weight isoform of tenascin-C is present, whereas in the tumor 
tissue, low and/or high molecular-weight isoforms are over-expressed. This result implies 
differential tenascin-C isoform expression in normal and neoplastic human colon tissue. This 
is in agreement with previous reports showing expression of the small isoform in normal 
stable tissues 57, while larger variants are detectable in diseased tissues including neoplasia, 
wound healing or inflammation 58-61. Immunohistochemical analysis of frozen sections of the 
same patients revealed prominent stromal staining for both tenascins. The stromal staining of 
tenascin-C and tenascin-W was confirmed on a frozen TMA containing 32 different colon 
cancer sections. This study revealed that all of the tumors were stained for both tenascins and 
that the staining correlated with the amount of tumor stroma present. Similar observations 
have been made in human breast tumors. Tenascin-W and tenascin-C were shown to be highly 
expressed in a large fraction of human breast tumors. In contrast to normal colon mucosae, 
which express tenascin-C, normal mammary parenchyma was negative for both tenascins 36.  
To summarize, in our first exploratory study we measured a higher concentration of serum 
tenascin-W in samples from colorectal cancer patients and breast cancer patients compared to 
controls. However, not all cancer patients did show elevated tenascin-W levels. The fact that 
tenascin-W is highly expressed in the tumor tissue of most extracts, is detected in all cancer 
sections by immunohistochemistry but is completely absent in normal tissue, suggests that 
tenascin-W is a better candidate tumor marker for colorectal cancer than tenascin-C, which is 
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also expressed in normal colon mucosa. The positive correlation between elevated serum 
tenascin-W and the presence of colorectal or breast cancer raises the possibility that elevated 
tenascin-W levels in serum or tissue might be of clinical importance. These observations 
warrant a follow-up study to evaluate the potential diagnostic or prognostic relevance of 
tenascin-W in colorectal cancer and possibly to other cancer types. 
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Figure Legends 
 
Figure 1 – Overview of the antibodies raised against tenascin-W  
(a) Schematic representation of the domain structure of human TNW. The recombinant full-
length TNW and the fragments that served as antigens to raise polyclonal and monoclonal 
antibodies are indicated by lines. The following symbols have been used to identify the 
structural domains: heptad repeats (wavy line), EGF-like repeats (diamonds), FNIII domains 
(boxes), FNIII domains generated by duplication (dark boxes), fibrinogen globe (circle). (b) 
Coomassie-stained gel (lanes 1-5) and western blot (lanes 6-10). (1, 6) TNW conditioned 
medium 10 µl, (2, 7) fibronectin 2.5 µg, (3, 8) fibrinogen 2.5 µg, (4, 9) purified TNC 2.5 µg, 
(5) purified TNW 2.5 µg and (10) purified hTNW 500 ng. Immunoblot analysis shows that 
the detection antibody pAb (FL) specifically recognizes TNW and that it does not cross-react 
with the other tested proteins. (c) The reactivity of pAb (FL) with purified tenascin-W (W) 
can be blocked by incubation with 10 μg/ml of purified tenascin-W (FLhTNW), but not with 
10 μg/ml of the bacterially expressed FNIII 3F/4 fragment, while the reactivity of pAb (3F/4) 
can be blocked by both tenascin-W preparations (d) Log-log presentation of a typical standard 
curve using mAb 29A as capture antibody, pAb (FL) as detection antibody, and a serial 
dilution of the purified TNW is shown. Detection limit was reached at TNW concentrations of 
about 0.005 mg/l. 
 
Figure 2 – Tenascin-W serum levels 
(a) TNW serum levels of healthy volunteers (n= 25, mean: 0.389 +/- 0.145 mg/l) and of non-
metastatic colorectal cancer patients (n=17, mean: 0.794 +/- 0.38 mg/l) are shown. There is a 
statistically significant increase in mean tenascin-W level (bar) in colorectal cancer patients 
compared to that in volunteers. (b) Serum TNC levels of healthy individuals and of colorectal 
cancer patients is displayed. They show an increase of the mean serum TNC level (n=17, 
mean: 0.98 +/- 0.24 mg/l) compared to that in healthy individuals (n=13, mean: 0.798 +/- 0.24 
mg/l). (c) Serum TNW levels in non-metastatic breast cancer patients (n=16, mean: 0.682 +/- 
0.44 mg/l) and of healthy volunteers (n=25, mean: 0.389 +/- 0.145 mg/l) are shown. The bars 
indicate the mean tenascin values. 
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Figure 3 – Tenascin-W expression in colorectal cancer 
(a) Eleven colorectal cancer extracts (T) and three normal colon tissues (N) were tested on 
immunoblots for the presence of TNW and TNC. Analysis revealed a basal expression of low 
molecular-weight isoform of TNC in the normal mucosa and up-regulation of mostly large 
TNC variants in the tumor tissue. The position of the recombinant high molecular weight 
TNC isoform loaded for comparison is indicated (arrowhead). TNW is detectable in a large 
fraction of tumoral tissues but not in normal colon mucosae. (b) Immunohistochemical 
analysis of frozen sections of patient L confirmed immunoblot results and showed strong 
staining in the tumor stroma for both tenascins. Whereas no staining was detectable in the 
normal tissue with respect to TNW, strong staining was observed for TNC in the muscularis 
mucosa. Calibration bar: 250 μm. N: normal; T: tumor. 
 
Figure 4 – Frozen colon tissue microarray 
Immunohistochemistry with a mAb against TNC, pAb (3F/4) against TNW and Hematoxylin 
and Eosin stained sections (H&E) of a frozen colon TMA of the patients indicated are shown 
(cf. Table III). Normal colon mucosa (patient 37) is negative for TNW, but positive for TNC. 
TNC is also strongly expressed in colon smooth muscle (patient 36). Patient 26 shows an 
example of a border of a tumor with the adjacent normal tissue. In the tumor patients 1-32 
(Table III) analyzed it was found that TNW is exclusively localized in the tumor stroma. In 
some patients, TNW-positive areas seemed to be a subset of the TNC-positive region (patient 
12). Patients 15 and 5 show large (+++) areas of tenascin positivity. Patients 4 and 13 display 
intermediate (++) to low (+) areas, respectively, of tenascin-W staining. In general, the 
staining correlates with the amount of tumor stroma present.   
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Abstract 
Glioblastoma (GBM) are highly invasive and aggressive brain tumors that show limited 
response to conventional therapies. We observed in human GBM lines frequent NOTCH2 
locus amplification and high Notch2 protein levels to coincide with expression of the tumor 
progression marker tenascin-C. Furthermore, RBPJκ, the Notch signaling co-factor required 
for transcription activation of target genes, was significantly co-expressed with tenascin-C in 
GBM of a tissue microarray (P=0.02). In the tenascin-C-negative glioma line Hs683, we 
found a missense mutation (L1711M) in the conserved RBPJκ-interacting RAM domain of 
Notch2. Expression of the wild-type activated forms of Notch2 or Notch1 in glioma cells 
triggered RBPJκ-dependent induction of tenascin-C transcription that was abolished by the 
L1711M mutation. Furthermore, transfection of activated Notch2 or Notch1 increased 
endogenous tenascin-C expression. Since addition of increasing amounts of tenascin-C 
stimulated glioma cell migration, this may represent a mechanism underlying the invasive 
properties of glioma cells controlled by Notch signaling and defines a novel oncogenic 
pathway in gliomagenesis to be targeted for therapeutic intervention in GBM patients. 
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Introduction 
Malignant gliomas are invasive tumors that can only transiently be controlled by surgery, 
radio-and chemotherapy (Louis et al., 2001; Maher et al., 2001; Merlo, 2003). Depending on 
histological subtype, median survival of glioma patients varies between 10 months in the 
prevalent glioblastoma (GBM) and 10 years in low-grade oligodendroglioma (OG) 
(Cairncross et al., 1998). This is reflected in distinct pathogenetic pathways operative in these 
different glioma entities associated with variable degrees of aggressiveness. Notch signaling 
is an evolutionary conserved pathway that controls cell fate and growth (Artavanis-Tsakonas 
et al., 1999). Ligand-dependent cleavage of the Notch transmembrane receptor releases the 
Notch intracellular domain (N-IC) into the cytoplasm. N-IC translocates to the nucleus, 
recruits and converts the transcriptional repressor RBPJκ/CBF1/Su(H)/CSL to induce 
expression of Notch targets such as hairy/enhancer of split (HES)-1 and HES-5 in humans 
(Allman et al., 2002; Artavanis-Tsakonas et al., 1999; Blaumueller et al., 1997; Jarriault et al., 
1995; Wilson & Kovall, 2006). Notch2 is expressed during brain development in cerebellum 
external granule layer and subventricular zones, where it maintains proliferation and prevents 
neuronal precursor differentiation (Solecki et al., 2001). Notch2 expression in postnatal brain 
is restricted to ventricular germinal zones and dividing immature glial cells (Tanaka & 
Marunouchi, 2003). Conversely, Notch2-targeted mice show increased apoptosis in neural 
tissues, leading to embryonic lethality (Hamada et al., 1999). An oncogenic Notch2 function 
has been reported in human B cell leukemia (Hubmann et al., 2002), as well as in 
medulloblastoma (Fan et al., 2004). Although Notch1 oncogenic activity has also been shown 
in gliomas and other malignancies (Purow et al., 2005) it can also act as a tumor suppressor, 
depending on the cellular context (Radtke & Raj, 2003). 
 
Tenascin-C (TN-C) is an extracellular matrix glycoprotein first identified in gliomas 
(Bourdon et al., 1983). High expression levels of perivascular TN-C correlates with shorter 
progression-free survival in glioma patients (Herold-Mende et al., 2002) and expression of 
stromal TN-C is increased in higher tumor grades with poor prognosis (Leins et al., 2003). In 
many cancers including brain tumors, TN-C expression correlates with invasiveness and 
formation of new vessels (for review see (Orend & Chiquet-Ehrismann, 2006)). In TN-C-
deficient mice, maturation of oligodendrocyte precursors is accelerated (Garcion et al., 2001). 
Furthermore, cardiac neovascularization is impaired in TN-C-deficient mice (Ballard et al., 
RESULTS - SUBMITTED 
 
100 
 
2006). Thus, TN-C promotes cell migration, controls differentiation and is critical for 
angiogenesis. 
 
We describe here that Notch signaling increases TN-C levels by gene transactivation, and that 
TN-C promotes migration of glioma cells. This indicates regulation of TN-C pro-migratory 
activity in invasive glioma by Notch signaling. 
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RESULTS 
Notch2, Notch1, RBPJκ and tenascin-C expression in gliomas 
Immunohistochemistry on glioma biopsies revealed strong Notch2 immunostaining in 
astrocytomas and GBM. In contrast, Notch2 protein was undetectable in OG and normal brain 
tissue [Figure 1a, left]. Real-time PCR-based genomic DNA dosage analysis revealed that 4/8 
GBM lines had amplification at NOTCH2 marker D1S2696, while LN18 exhibited local 
haploidy [Figure 1b]. Fluorescent in situ hybridization (FISH) showed that NOTCH2 
amplifications in U373 and U343 lines resulted from chromosome 1 trisomy [Supplementary 
Figure S1]. The glioma cell line expressing OG markers Hs683 (Branle et al., 2002) contained 
one Notch2 gene copy per diploid genome, reminiscent of the prevalent OG chromosome 1p 
loss extending to Notch2 (Boulay et al., 2007). Western blot analysis revealed concordance 
between genomic status and protein levels [Figure 1b]. Likewise, immunohistochemical 
analysis of TN-C in the same biopsies revealed high TN-C expression in GBM, and barely or 
not detectable levels in OG and normal white matter [Figure 1a, right]. Furthermore, in all cell 
lines tested, there was a striking coincidence between Notch2 and TN-C protein levels, 
particularly visible in Hs683 and LN18 cells with low Notch2 levels and absence of 
detectable TN-C [Figure 1c]. Finally, Notch1, Notch2, and RBPJκ protein levels were 
compared to Notch signaling activation assessed by HES-1 transcript levels [Figure 1c]. 
RBPJκ was present in all GBM lines and decreased amounts of Notch1 or Notch2 were 
accompanied by lower HES1 expression, as can be seen in Hs683, LN18 and LN401 cells 
[Figure 1c]. 
 
To extend our immunohistochemical analysis, we made use of GBM tissue microarrays 
revealing labeling frequencies of 83% (118/143) for Notch2, 59% (84/142) for Notch1, 37% 
(54/146) for RBPJκ and 55% (70/127) for TN-C. Thus, Notch2 was more frequently 
expressed than Notch1 and there was a significant association between RBPJκ and TN-C 
expression (P=0.02) [Table1; Figure 2]. This significant correlation suggested the possibility 
of a causal relationship and trans-activation of TN-C by Notch/RBPJκ signaling was 
considered. 
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The TN-C promoter contains a RBPJκ-responsive element 
We analyzed the TN-C promoter sequences for the presence of a RBPJκ binding motif. 
Alignment of the upstream sequences of human and murine Notch target genes HES1 and 
HES5 with those of TN-C revealed the presence of a conserved RBPJκ binding motif 
GTGGGAA at the same distance from the TATA box in each of these genes [Figure 3a]. We, 
therefore, tested whether N2-IC and N1-IC were able to induce luciferase reporter gene 
expression driven by a 102 bp fragment of a human TN-C minimal promoter containing the 
RBPJκ binding motif [Figures 3a]. Co-transfection of Hs683 cells with a plasmid expressing 
either N2-IC or N1-IC both led to a two-fold increase compared to the basal luciferase activity 
in the presence of a control plasmid [Figure 3b, top]. 
 
To test whether this induction is dependent on RBPJκ function, point mutations, previously 
described to prevent RBPJκ binding (Tun et al., 1994) were introduced into the potential 
RBPJκ binding site of the TN-C promoter. Transfection of mutant promoter constructs M1 
and M2 that prevent RBPJκ binding produced basal luciferase levels, but no longer allowed 
induction by N2-IC [Figure 3b, bottom]. Consistently, co-transfection of a plasmid expressing 
a dominant negative RBPJκ mutant (Chung et al., 1994) impaired N2-IC-mediated induction 
of the TN-C promoter [Figure 3c]. 
 
The tenascin-C negative line Hs683 contains a Notch2 mutation 
In glioma cells, we sequenced Notch2 fragments encoding N2-IC and covering mutation 
hotspots for gain- or loss-of-function described in Drosophila Notch (Brennan et al., 1997; 
Rebay et al., 1993), NOTCH1 (Mansour et al., 2006) and NOTCH2 (McDaniell et al., 2006). 
Interestingly, the OG line Hs683 had a C-to-A mutation in Notch2 codon 1711 resulting in the 
substitution of leucine by methionine [Figure 4a]. Leucine 1711 is conserved throughout 
vertebrate Notch2 proteins [Figure 4b] and is located within the RBPJκ-interacting RAM 
domain (Tamura et al., 1995; Wilson & Kovall, 2006). Co-expression of the N2-ICL1711M 
mutant with the TN-C promoter construct no longer increased luciferase activity [Figure 4c]. 
Therefore, the Notch2 present in the HS683 cells seems to be non-functional. 
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Notch signaling increases endogenous tenascin-C levels 
We further tested whether Notch signaling was able to induce the expression of endogenous 
TN-C protein. Since the abundant TN-C levels produced by GBM cell lines may mask any 
further increases, we focused on fibroblast lines Detroit 551 and MRC-5 that secrete moderate 
amounts of TN-C. Supernatants of fibroblasts transfected with N2-IC showed increased 
accumulation of TN-C in the medium compared to the controls [Figure 5a, top], while 
secreted fibronectin levels were similar [Figure 5a, bottom]. The same stimulation of 
tenascin-C expression was seen after transfection of N1-IC, but not with the mutant N2-
ICL1711M construct [Figure 5b]. 
 
Tenascin-C enhances glioma cell migration 
To test whether increased TN-C expression is able to alter the dynamics of cell migration, 
transfilter migration assays were performed with the TN-Cnegative Hs683 cells. Addition of 
increasing amounts of purified TN-C stimulated the migratory capacity of TN-C-negative 
Hs683 cells to an intermediate level to that of TN-C-positive LN319 cells [Figure 6]. 
 
In summary, we showed that RBPJκ-dependent Notch signaling transcriptionally activates 
TN-C expression, and that addition of purified TN-C in turn promotes cell migration. Taking 
these results together, they provide a potential mechanism for oncogenic Notch signaling in 
gliomagenesis. 
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DISCUSSION 
Notch2 expression in GBM and OG 
Notch2 is expressed in immature glial cells of ventricular germinal zones of normal brain 
(Irvin et al., 2001; Tanaka & Marunouchi, 2003; Wang & Barres, 2000), concordant with the 
hypothesis of an undifferentiated state of neoplastic cells in GBM. Consistently, the gene 
promoter of nestin, a marker for neural precursors and of GBM contains also a RBPJκ 
responsive element (Shih & Holland, 2006), implying that Notch2 may be involved in 
maintaining glioma cells in an undifferentiated state. However, the fact that RBPJκ target 
HES-1 drives astrocytic cell fate (Wu et al., 2003) argues also for a role of Notch2 in 
astrocytic differentiation. It has been shown that primary GBM show high HES-1 contents, 
while astrocytoma progression coincides with decreasing HES-1 levels (Somasundaram et al., 
2005). Since HES-1 is under direct control of both Notch proteins, the question whether 
Notch1 plays redundant or complementary roles to Notch2 in glioma progression remains 
open. 
 
Conversely, the Notch2 loss-of-function mutation in Hs683 cells provides an inactivation 
mechanism of Notch2 in OG, in addition to homozygous deletions detected in primary OG 
with 1p loss (Boulay et al., 2007). Thus, OG development appears dependent on Notch2 loss. 
Although both, Notch1 and Notch2 proteins expressed in the glial lineage are inducers of TN-
C, Notch2 co-expression with TN-C seemed to be more common. This association may be 
based on the frequent Notch2 gene amplification and high protein expression we found in 
GBM. 
 
A RBPJκ-responsive element in the TN-C gene promoter 
The significant association between RBPJκ and TN-C expression in a GBM tissue microarray 
together with the identification of a RBPJκ-responsive element in a minimal TN-C promoter 
provide a novel mechanism of TN-C trans-activation. 
 
Molecular cooperation between Notch2 and RBPJκ has been suggested in B cell 
development, where Notch2- and RBPJκ-targeted mice present a common phenotype both 
lacking a B cell subset (Saito et al., 2003; Tanigaki et al., 2002), and in B cell leukemia, 
where Notch2 together with RBPJκ upregulate CD23a transcription (Hubmann et al., 2002). 
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Nevertheless, half (31/62) of TN-C-positive GBM on the tissue microarray were RBPJκ-
negative, suggesting RBPJκ-independent regulatory pathways. In human fibroblasts, the TN-C 
promoter is activated by platelet-derivate growth factor (PDGF) and transforming growth 
factor (TGF)-β (Jinnin et al., 2004; Jinnin et al., 2006). Since TGF-β signaling promotes 
PDGF-beta-dependent cell proliferation in glioma (Bruna et al., 2007), activation of the TN-C 
promoter by TGF-β signaling may also apply in glioma. 
 
The Notch-Tenascin-C network 
TN-C-deficient mice show compromised proliferation/migration of neural precursors, and 
accelerated oligodendrocyte differentiation (Garcion et al., 2001). Consistently, GBM lines 
and biopsies showed strong TN-C expression, while OG did not, although an OG subset has 
been described as moderately positive (McLendon et al., 2000). Strong TN-C expression is 
associated with the invasive front in many tumors types and is a diagnostic marker for glioma 
progression, implying a role for TN-C in tumor promotion. (for review see (Orend & Chiquet-
Ehrismann, 2006). This supports the hypothesis of Notch2/RBPJκ/TN-C signaling to be 
operative in GBM, but not OG development. 
 
From a clinical point of view, conventional therapeutic interventions based on tumor resection 
and radio- and chemotherapy have only moderately improved glioma patient survival over the 
past decades (Stupp et al., 2005). In addition to directly targeting TN-C (Merlo et al., 1997; 
Reardon et al., 2002), our data suggest the use of drugs blocking Notch signaling. We propose 
that the Notch/RBPJκ/TN-C pathway regulates tumor cell migration, a hallmark of invasive 
GBM. This molecular cascade provides a novel mechanism through which Notch acts in 
neoplastic transformation and possibly in normal development of the neuronal and glial cell 
lineages. 
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MATERIALS & METHODS 
Cell lines and antibodies 
Cells were grown in Dulbecco’s Modified Eagles Medium with 10% fetal calf serum and 1% 
Glutamine. Immunoreactions were performed with monoclonal antibodies anti-Notch2 
C651.6dbHN and anti-Notch1 bTAN20 (Zagouras et al., 1995) (Developmental Studies 
Hybridoma Bank, University of Iowa, USA), anti-TN-C B28-13 (Schenk et al., 1995), anti-
RBPJκ (Institute of Immunology,Tokyo, Japan), anti-actin (Sigma, Saint-Louis MO, USA) 
and antiserum against fibronectin (Ehrismann et al., 1981). 
 
Glioma biopsies and immunohistochemistry 
Paraffin sections of formalin-fixed tissue samples were obtained from the University of Basel 
Department of Neuropathology. Tumors were diagnosed and graded according to the WHO 
Classification of Tumors of the Nervous System. Immunohistochemistry was performed with 
anti-Notch2 and anti-TNC using an overnight incubation at 4°C of a 1:50 dilution. Bound 
antigens were detected using avidin-biotin-peroxidase (Vectastain, Elite kit; Vector 
Laboratories) and sections were weakly counterstained with hematoxylin. 
 
Nucleic acid extraction and analysis 
Genomic DNA was extracted using the genomic DNA purification kit (Qiagen, Hilden, 
Germany). RNA was isolated using Trizol (Invitrogen, Carlsbad, CA, USA), reverse-
transcribed with the ThermoScript RT-PCR system (Invitrogen, Carlsbad, CA, USA). Real-
time quantitative PCR was performed on an ABI Prism sequence 7700 detector (PE Applied 
Biosystems, Foster, CA, USA) at microsatellite marker D1S2696 using primers 
gaattacatcccaggcaatctga and cacacaacaggcccctaatca and probe FAM-
agcccatgctcattcccactacactgg- TAMRA. GAPDH primers aatgggactgaggctcccac and 
ttatgggaaagccagtcccc and probe FAM-atccaagactggctcctccctgctg-TAMRA. Notch2 cDNAs 
from glioma cells were sequenced at mutation hot spots, i.e. EGF repeats 11-14, 24-25, 29 
and 32, Lin-12 domains and N2-IC. The Notch2 mutation L1711M found in Hs683 cDNA 
was confirmed by sequencing genomic DNA. 
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Western blot analysis 
Cell extracts and conditioned media were separated by SDS-PAGE and electroblotted to 
PDVF membranes (Millipore, Bedford MA, USA). Proteins were detected with primary and 
secondary antibodies and blots developed using Super Signal (Pierce, Rockford IL, USA) on 
Kodak BioMax MR Films (Rochester, NY, USA). Protein bands were quantified using the 
software GeneTools (SynGene, Cambridge, UK). 
 
Tissue microarray 
The tissue micro array comprising 190 glioblastoma has been constructed from archived 
paraffin blocks at the University Hospital in Lausanne, Switzerland (Godard et al., 2003). 
Immunohistochemical determination for tenascin-C (dilution 1:2500), anti-RBPJκ (1:120), 
Notch2 (1:100) and Notch1 (Abcam, Cambridge, UK) (1:200) was performed according to 
standard procedures for paraffin sections using a high temperature epitope retrieval technique 
in citrate buffer (pH 6.0; pressure cooker, 3 to 5 minutes) and overnight incubation with the 
primary antibody. The immunostaining was scored semiquantitatively from low (score 0-1) 
versus high expression score (2-3) and was used for statistics by Fisher’s exact test. Tumors 
were ordered by similarity of expression profiles (scores 0 to 3) using the SPIN software 
(Tsafrir et al., 2005). 
 
Fluorescent in situ hybridization 
Fluorescent in situ hybridization on metaphase chromosomes of cell lines was performed 
using the Nucleic Acid Labelling Systems kit (Q-BioGene, Illkirch, France). 
 
Plasmids 
Activated Notch2 (N2-IC, from nucleotides 5107 to 7425 of Notch2 cDNA sequence 
AF308601) was cloned into plasmid pcDNA3 (Invitrogen, Carlsbad, CA, USA). Mutations in 
the Notch2-IC (L1711M) and in the RBPJκ binding site (Tun et al., 1994) were obtained by 
site-directed mutagenesis (Stratagene, La Jolla, CA, USA). The Notch1 construct 
(Capobianco et al., 1997) was kindly provided by Dr. Radtke, and the dominant-negative 
RBPJκ plasmid (Chung et al., 1994), by Dr. Honjo. The TN-C promoter construct included 
102bp 5’flanking sequence from the transcription start and 97bp of the first exon. 
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The reporter construct was cloned with the Expand High Fidelity PCR System (Roche, 
Rotkreuz, Switzerland) using the primer pair gagctagcctttaattcgccaactg / 
gactcgagctgcctttgtgcccacggag with genomic DNA from HEK293 cells as template and cloned 
into the pGL3 luciferase reporter vector (Promega, Madison WI, USA). 
 
Transfections and reporter gene assays 
Transfections were performed using Fugene (Roche, Rotkreuz, Switzerland). For the reporter 
gene assays, Hs683 cells were seeded in 6-well plates and transiently transfected with 1 μg 
TN-C luciferase reporter vector, 1 μg expression plasmid, and 0.1 μg Renilla Luciferase 
reporter vector phRL-TK for standardization (Promega, Madison WI, USA). Cells were 
harvested after 24 hours and assayed for luciferase activity using the Dual-Luciferase 
Reporter Assay System (Promega, Madison WI, USA). Luciferase activity was measured 
from at least three independent experiments in a Mithras LB940 Luminometer (Berthold 
Technologies, Bad Wildbad, Germany). Western blots showing similar levels between N2-
ICWT and N2-ICL1711M in transfected cells ruled out instability of N2-ICL1711M. 
 
Transwell migration assays 
Transwell migration assays were performed using modified Boyden chamber units with 
polycarbonate filters of 8μm porosity (Costar, Appleton Woods, Birmingham, UK). The 
lower side of the filter was coated with 10μg/ml fibronectin for 2 hours at room temperature. 
The bottom chamber was filled with serum-free DMEM containing 0.1% BSA plus/minus 
increasing amounts of purified human TN-C. Cells (104 cells/well in serum-free DMEM) 
were plated in the upper chamber and incubated for 16 hours at 37°C. After removal of the 
remaining cells from the upper surface of the filter, migrated cells at the bottom of the filter 
were fixed with 3.7% formaldehyde in PBS and stained with 0.1% crystal violet. For each 
condition, cells in five fields of three independent experiments were counted. 
 
Statistical analyses 
Kruskal-Wallis test was used for significance of genomic copy dosage. Significances of 
reporter gene expression and endogenous TN-C expression were established with the Student 
t test available at the web server of St. John’s University, St. Joseph, MN (USA). 
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LEGENDS TO FIGURES 
 
Figure 1. Notch and tenascin-C expression in glioblastoma 
(a) Immunostaining of normal white matter (top), oligodendroglioma (middle) and 
glioblastoma (bottom) biopsies with anti-Notch2 (left) and anti-TN-C (right). Notch2 and TN-
C stainings were performed on sections of the same biopsies. (b) Detection of genomic 
amplifications at marker D1S2696 in glioma lines by real-time quantitative PCR. ΔCt value 
of 0 corresponds to normal diploidy. Notch2 Genomic status (n) is calculated as 2x2-ΔCt. All 
experiments were done in triplicate. Average values and standard deviations (error bars) are 
based on two independent experiments. P-value for comparison of all three groups (>2n; 2n; 
<2n): P=0.0002. (c) Notch2, TN-C, Notch1 and RBPJκ immunodetection in glioma cells. For 
each experiment, the corresponding actin standard is shown below. (d) Assessment of Notch 
signaling activity in glioma cells by real-time quantitative PCR of HES-1 transcripts. ΔCt 
value of 0 corresponds to fetal brain level. HES-1 amounts relative to fetal brain baseline 
calculated as 2ΔCt. 
 
Figure 2. Visualization of Notch1, Notch2, RBPJκ and TN-C expression in 96 GBM 
Protein expression was determined by immunohistochemistry on a GBM tissue microarray 
and scored 0 (indigo, no expression) to 3 (red, high expression). 96 0f the 190 spots could be 
classified for all four proteins. Data are ordered using the SPIN software (Tsafrir et al., 2005). 
 
Figure 3. The tenascin-C promoter contains a functional RBPJκ responsive element 
(a) Sequence alignment of human (h) and mouse (m) HES5, HES1 and TN-C promoters. 
Conserved nucleotides are uppercase and marked by dots. TATA boxes and RBPJκ binding 
motifs are highlighted in black. (b) Notchdependent induction of luciferase driven by the 
human TN-C promoter occurs when the wild-type (WT) RBPJκ binding site is present, but not 
with M1 or M2 mutants. Average values and standard deviations (error bars) are based on 
three independent experiments. Significance of N2-IC induction on GTGGGAA WT vs. 
control pcDNA3 and M1/M2 mutations: P<0.008. (c) A dominant-negative (DN) RBPJκ 
mutant impairs Notch2-dependent induction of TN-C transcription. Significance of N2-IC 
induction vs. pcDNA3 and RBPJκDN: P<0.008 and of N1-IC vs. pcDNA3: P<0.035. 
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Figure 4. Notch2-IC but not the mutant Notch2-IC trans-activates the tenascin-C promoter 
(a) Electrophoretogram of the Hs683 mutation L1711M. (b) Top. The N2-IC domains. 
Abbreviations: RAM, RBPJκ-binding site; NLS, nuclear localization signal; TAD, trans-
activation domain; PEST, serine/threonine-rich domain. Bottom. Sequence alignment of the 
Hs683 Notch2 mutation with wild-type Notch2 RAM. Conserved aminoacids are uppercase, 
the mutation is highlighted. (c) Notch2-dependent induction of the TN-C promoter is impaired 
by mutation L1711M. Significance of N2-ICWT induction vs. pcDNA3 and N2- ICL1711M: 
P<0.02. 
 
Figure 5. Notch signaling triggers endogenous tenascin-C production 
(a) Time course of Notch2-dependent endogenous TN-C production. Detection of TN-C and 
fibronectin on western blots of supernatants from transfected Detroit 551 and MRC-5 
fibroblasts collected 24 and 48 hrs after transfection with Notch2-IC or the control plasmid 
pcDNA3. Graphs show quantification of TN-C (top) and fibronectin (bottom) protein bands. 
(b) Transfection of wild-type Notch1-IC and Notch2-IC but not the mutated Notch2-
ICL1711M lead to an increase of TN-C levels in fibroblasts. 
 
Figure 6. Tenascin-C promotes glioma cell migration 
Migration assays were performed in modified Boyden chambers with Hs683 (TN-C-) and 
LN319 (TN-C+) cells in the presence or absence of purified TN-C protein In the lower 
chamber. After 16 hrs, migrated cells were counted and numbers normalized to Hs683 cells in 
the absence of TN-C. Average values and standard deviations (error bars) are based on three 
independent experiments. Significance: Hs683 vs. Hs683 + 10μg/ml TN-C: P<0.001; Hs683 
vs. LN319: P< 0.001. 
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Table 
 
 
 
 
 
 
 
 
 
a Fisher’s exact test, 2-sided 
 
 
 
Figure 1 
RBPJk-high RBPJk-low Total
TNC-high 31 31 62
TNC-low 10 29 39
Total 41 60 101 p=0.021a
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Figure 6 
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Supplemental material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S1. Fluorescent in situ hybridization of dGreen labeled BAC clone RP5-1042I98 (GeneBank 
accession: AL359752) and rhodamine-labeled 1q telomeric probe D1S3739 on metaphase 
chromosomes of U373 and U343 cells. The BAC RP5-1042I98 labels the 11p11 area plus the 
1q21.1 pericentric duplication. 
 
U373
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III.2.2 Opposite effect of fluticasone and salmeterol on fibronectin and 
tenascin-C expression in primary human lung fibroblasts 
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Abstract 
Airway remodeling is a key feature of asthma and chronic obstructive pulmonary disease 
(COPD). The remodeling process involves the deposition of extracellular matrix (ECM) 
proteins within the airways. Current therapies for asthma and COPD consist of inhaled 
corticosteroids and long-acting β2-agonists. However, their effect on airway remodeling is not 
well understood so far. In this study we investigated the effect of fluticasone and salmeterol, 
either alone or in combination, on fibronectin and tenascin-C protein and mRNA levels in 
primary human lung fibroblasts. In our model, fibroblasts cultured in serum-free medium 
represented a non-inflammatory condition and stimulation with 5% FCS and/or TGF-β1 
mimicked an inflammatory environment with activation of tissue repair. In both conditions, 
fluticasone increased fibronectin transcript and protein levels, whereas it decreased those of 
tenascin-C. Salmeterol neither affected fibronectin and tenascin-C synthesis nor did it 
influence the effect of fluticasone when applied in combination. Furthermore, we found that 
treatment with fluticasone had an opposite effect on extra domain A- and B-containing 
fibronectin isoforms generated by alternative splicing compared to total fibronectin transcript 
levels, whereas tenascin-C isoforms were not differently modulated by fluticasone compared 
to total tenascin-C transcript levels. Our results indicate that standard therapies for 
inflammatory lung disorders influence ECM protein composition and relative expression 
levels. 
 
 
Keywords: fibronectin, tenascin-C, human lung fibroblasts, asthma therapy 
 
Abbreviations: COPD, chronic obstructive pulmonary disease; ECM, extracellular matrix; 
EDA/B, extra domain A/B; LABA, long-acting β2-agonist; TGF-β1, transforming growth 
factor β1 
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INTRODUCTION 
Asthma and chronic obstructive pulmonary disease (COPD) are among the world’s most 
prelevant diseases. Both are characterized by chronic inflammation and tissue remodeling 
resulting in irreversible structural changes in the lung. Prominent features of the airway 
remodeling process include thickening of the lamina reticularis, enlargement of bronchial 
smooth muscle mass due to hyperplastic and hypertrophic smooth muscle cells, increase in 
vascularity, and increase of extracellular matrix (ECM) protein deposition within the airways 
(Roche, Beasley, Williams, & Holgate, 1989; Busse, Elias, Sheppard, & Banks-Schlegel, 
1999; Bousquet, Jeffery, Busse, Johnson, & Vignola, 2000; Jeffery, 2001; Bergeron & Boulet, 
2006). Whether pathological ECM deposition is the result or the cause for chronic airway 
inflammation is not yet clear. However, it is well established that the ECM is not only a 
passive component of tissues, but rather plays a very active and dynamic role in regulating 
cell proliferation, differentiation, apoptosis, adhesion, and migration. Furthermore, the ECM 
has architectural roles during development and tissue repair and provides positional and 
environmental information essential for tissue maintenance and function (Bosman & 
Stamenkovic, 2003). Therefore, it is not surprising that the ECM profile in the airways of 
healthy individuals differs both in quantity and composition from that of asthmatic and COPD 
subjects. Whereas deposition of collagen IV and elastin is decreased in asthmatic patients 
compared to healthy individuals, deposition of other specific ECM proteins, including 
collagen I, III, and V, fibronectin, tenascin, versican, and laminin is increased (Roche, 
Beasley, Williams, & Holgate, 1989; Bousquet et al., 1992; Altraja et al., 1996; Laitinen et 
al., 1997; Roberts & Burke, 1998). 
 
Lung fibroblasts are important mediators of the lung tissue repair process as they are involved 
in cell proliferation and synthesis of ECM components. Among the various ECM proteins, 
lung fibroblasts secrete tenascin-C and fibronectin, two large multifunctional and 
multidomain ECM glycoproteins highly expressed during morphogenesis and tissue repair. 
Tenascin-C is the founding member of the tenascin family which includes three other 
members: tenascin-R, -X and –W (Chiquet-Ehrismann & Chiquet, 2003). All tenascins 
display complex, highly restricted, and dynamic patterns of expression. Tenascin-C, which is 
subjected to alternative splicing, shows high expression during embryogenesis and 
organogenesis, but reduced and restricted expression in adult organisms (Jones & Jones, 
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2000). However, there is a sharp re-expression of tenascin-C under pathological conditions 
such as inflammation, infection, tissue remodeling, wound healing, and tumorigenesis 
(Chiquet-Ehrismann & Chiquet, 2003). Tenascin-C expression in the healthy lung is either 
absent or weakly detected only in small vessels and basement membranes of large bronchi. In 
contrast, asthmatic lung tissue shows high tenascin-C expression in the subepithelial ECM 
(Laitinen et al., 1997; Amin et al., 2000; Laitinen, Altraja, Karjalainen, & Laitinen, 2000; 
Chiquet-Ehrismann & Chiquet, 2003; Karjalainen et al., 2003). Strong tenascin-C expression 
has also been reported in patients suffering from interstitial pneumonia and sarcoidosis (Kuhn 
& Mason, 1995; Kaarteenaho-Wiik, Mertaniemi, Sajanti, Soini, & Paakko, 1998). Recent data 
suggest that tenascin-C, which is particularly abundant at inflammation sites, might be 
involved in the pathogenesis of asthma (Nakahara et al., 2006). 
 
Fibronectin is highly found in all major groups of vertebrates as insoluble component of many 
ECM and as soluble protein in many body fluids (Hynes, 1990). Although fibronectin is 
encoded by a single gene, it is subjected to alternative splicing resulting in 20 variants 
(Kornblihtt, Vibe-Pedersen, & Baralle, 1984; Kornblihtt, Umezawa, Vibe-Pedersen, & 
Baralle, 1985; Hynes, 1990; Pankov & Yamada, 2002). The most frequent splicing isoforms 
occur within the central set of type III repeats (EDA, EDB and IIICS). These splice variants 
are differentially expressed in development and disease (Ffrench-Constant & Hynes, 1989; 
Ffrench-Constant, Van de Water, Dvorak, & Hynes, 1989; Peters & Hynes, 1996) and are 
known to have various functions (Pankov & Yamada, 2002). EDA- or EDB-containing 
fibronectin are expressed at very low levels in adults (Peters, Chen, & Hynes, 1996), but their 
levels are markedly increased during pathological remodeling processes and cancer 
(Carnemolla et al., 1989; Matter et al., 2004; Trachsel, Kaspar, Bootz, Detmar, & Neri, 2007). 
 
Several studies have shown increased fibronectin levels in body fluids as well as in the lung 
ECM of subjects with COPD, asthma or other interstitial lung diseases, claiming that 
fibronectin might contribute to the pathogenesis of lung abnormalities seen in these 
pathologies (Mattoli, Mattoso, Soloperto, Allegra, & Fasoli, 1991; Campbell et al., 1993; 
Gupta, Reinhart, & Bhalla, 1998; Meerschaert, Kelly, Mosher, Busse, & Jarjour, 1999; 
Trifilieff, El-Hashim, & Bertrand, 2000). Moreover, similarly to tenascin-C, fibronectin has 
been implicated in the regulation of cell proliferation, differentiation, spreading, and 
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migration (Pankov & Yamada, 2002). In asthma and COPD the proliferation and migration of 
mesenchymal cells is increased and contributes to the thickening of the airway walls 
(Bergeron & Boulet, 2006). 
 
Current asthma and COPD therapies include inhaled corticosteroids and long-acting β2-
agonists (LABA) applied either alone or in combination. Corticosteroids have a well-
described anti-inflammatory effect, however, their influence on airway remodeling remains 
controversial (Olivieri et al., 1997; Pauwels et al., 1997; Hoshino, Takahashi, Takai, & Sim, 
1999; Boulet et al., 2000; Bergeron et al., 2005; Tomic, Lassiter, Ritzenthaler, Rivera, & 
Roman, 2005; Ward et al., 2005; Goulet, Bihl, Gambazzi, Tamm, & Roth, 2007). More than a 
decade ago, Pauwels et al. have shown that the addition of inhaled formoterol to budesonide 
resulted in better improvement of clinical outcome in asthma patients than higher dose of 
budesonide (Pauwels et al., 1997). However, the effect of combined corticosteroids and 
LABA on lung ECM synthesis and deposition remains to be fully elucidated. 
 
In the present study, we investigated the effect of corticosteroids and LABA, alone or in 
combination, on tenascin-C and fibronectin expression in primary human lung fibroblasts. As 
previously described, we used two experimental conditions in our culture model: a serum-
deprived medium representing a non-inflammatory environment and stimulation with 5% 
FCS and/or TGF-β1 mimicking an early stage of inflammation with vessel leakage and 
activated tissue repair (Goulet, Bihl, Gambazzi, Tamm, & Roth, 2007).   
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MATERIALS AND METHODS 
Cell culture 
Primary human lung fibroblasts were established from non-diseased peripheral lung tissue 
samples obtained from patients undergoing lung resection following approval by the ethics 
committee (Faculty of Medicine, University Hospital Basel, Switzerland). Cells were grown 
in RPMI 1640 (Cambrex Bio Science, Verviers, Belgium) supplemented with 10% FCS 
(GIBCO BRL Invitrogen, Basel, Switzerland) and 1% MEM-vitamins (Cambrex Bio 
Science). Fibroblasts were stimulated with recombinant human TGF-β1 (2.5 ng/ml; Sigma, 
Schnelldorf, Germany) and treated with fluticasone and salmeterol (10-7 M; GlaxoSmithKline, 
London, UK). Culture conditions and optimal drug doses have been determined previously 
(Goulet, Bihl, Gambazzi, Tamm, & Roth, 2007). Prior to any treatment, cells were serum-
deprived for 24 h in 0.3% human albumin. Fibroblasts between passages 3 and 6 were used 
for all experiments. 
 
Reverse transcriptase-polymerase chain reaction 
Confluent serum-deprived fibroblasts were treated with fluticasone and/or salmeterol (10-7 M) 
in 0.3 % albumin or 5% FCS for 48 h. Total RNA was extracted using the RNeasy Mini kit 
(Qiagen GmbH, Hilden, Germany) and reverse-transcribed using M-MLV Reverse 
Transcriptase (Promega, Madison, WI, USA). PCR was performed using the fibroblast 
cDNAs as templates and primers amplifying specific amplicons of GAPDH, FN, TN-C, TN-C 
isoforms, and the FN splicing isoforms EDA and EDB (Microsynth AG, Balgach, 
Switzerland; Table 1). PCR conditions were initial denaturation at 94˚C for 2 min then 
denaturation at 94˚C for 30 sec, primer annealing at 55˚C for 30 sec and extension at 72˚C for 
1 min for 28 cycles. PCR amplicons were size fractionated by electrophoresis on 1.5% 
agarose gels and visualized by ethidium bromide stain under UV light. The intensity of each 
band was analyzed by densitometry using the software Gene Tools (SynGene, Cambridge, 
UK) and the relative mRNA expression of target gene was normalized to the GAPDH control. 
Results are expressed as relative to controls (without drug treatment) which were defined as 1. 
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Western Blotting and Quantification 
30 μl of collected conditioned medium of primary human lung fibroblasts were mixed with 10 
μl of 4x reducing SDS-PAGE sample buffer, boiled for 5 min at 95°C and loaded onto a 6% 
SDS-polyacrylamide gel. After electrophoresis, proteins were electro-transferred onto a 
polyvinyldifluoride membrane (Millipore, Billerica, MA, USA) using a semi-dry blotting 
apparatus (Millipore). Afterwards, membranes were stained with amido black to control equal 
protein loading. After blocking for 1 h at room temperature in TBS containing 0.05% Tween 
and 5% skim milk powder, membranes were incubated overnight at 4°C with either the 
monoclonal antibody B28-13 raised against human tenascin-C (1:100) (Schenk, Muser, 
Vollmer, & Chiquet-Ehrismann, 1995) or the monoclonal anti-human fibronectin antibody 
(1:1000) (Sigma, Buchs, Switzerland). Membranes were washed 3 times with TBS containing 
0.05% Tween and then incubated with goat anti-mouse IgG coupled to horseradish peroxidase 
(1:10 000) (MP Biomedicals, Illkirch, France) for 1 h at room temperature. Blots were 
developed using Super Signal (Pierce, Rockford, IL, USA) and finally exposed on Kodak 
BioMax MR Films (Kodak, Rochester, NY, USA). 
 
For Western blot quantification, the software Gene Tools was used. Results represent the 
quantification of three different blots using three different primary human lung fibroblasts cell 
lines. Graphs are expressed as relative to controls (without drug treatment) which were 
defined as 100%. 
 
Statistical analysis 
Data are expressed as means ± SEM. Statistical significances were established with the 
Student’s t-test (available at the web server hosted by St. John’s University, St. Joseph, MN, 
USA: www.physics.csbsju.edu/stats/t-test.html). Differences were considered significant if 
p<0.05 compared to control. 
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RESULTS 
5% FCS and TGF-β1 increase the expression of fibronectin and tenascin-C 
Confluent fibroblasts cultured in serum-free medium, mimicking a non-inflammatory 
environment secreted a moderate constitutive level of fibronectin and tenascin-C detectable 
after 48 h by immunoblotting (Fig. 1). These control values were defined as 100% for further 
comparisons. Since we have shown previously that the addition of 5% FCS initiated a pro-
inflammatory response in primary human lung fibroblasts (Goulet, Bihl, Gambazzi, Tamm, & 
Roth, 2007) we investigated the effect of FCS on fibronectin and tenascin-C synthesis. 
Stimulation with 5% FCS showed only a slight increase of fibronectin levels but did not reach 
significance compared to control (p=0.06) (Fig. 1A). In contrast, 5% FCS significantly 
increased tenascin-C levels by more than 2.5-fold compared to 0.3% albumin (p<0.001) (Fig. 
1B). In order to investigate the effect of TGF-β1 which can function either as a pro- or anti-
inflammatory cytokine on inflammatory cells, we treated fibroblasts with TGF-β1 under both 
experimental conditions. Addition of TGF-β1 into serum-free medium significantly 
augmented fibronectin (p<0.01) and tenascin-C levels (p<0.001) compared to control. TGF-β1 
in the presence of 5% FCS significantly increased fibronectin levels by 3-fold compared to 
0.3% albumin (p<0.001) and more than 2-fold compared to the presence of 5% FCS alone 
(p<0.001) (Fig. 1A). Since tenascin-C levels were already very high in the presence of 5% 
FCS, we did not detect a further increase by treatment with TGF-β1 (Fig. 1B). 
 
 
Fibronectin and tenascin-C are differently regulated by fluticasone and salmeterol in the 
presence or absence of 5% FCS and/or TGF-β1 
Next we evaluated by immunoblotting the effects of fluticasone and salmeterol, applied alone 
or in combination, in the presence or absence of 5% FCS on fbronectin and tenascin-C 
synthesis (Fig. 2). Under serum-free condition, fluticasone led to an increase in fibronectin 
expression compared to control (p<0.01), whereas salmeterol had no effect. Combined 
fluticasone and salmeterol increased fibronectin levels (p<0.001), similarly to fluticasone 
administration alone (Fig. 2A). Fluticasone had an opposite effect on tenascin-C levels, which 
were significantly decreased by 5-fold compared to control (p<0.01). Salmeterol alone did not 
modulate tenascin-C expression compared to control nor did it affect the decrease observed 
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with fluticasone in combination (Fig. 2B). Inflammatory conditions with 5% FCS stimulation 
did not influence the effects of both drugs on fibronectin and tenascin-C expression in 
comparison to the one observed in serum-deprived fibroblasts. Indeed, fluticasone augmented 
fibronectin levels (p<0.01), whereas it decreased tenascin-C levels secreted into the 
conditioned medium (p<0.001). Salmeterol administration either alone or in combination, did 
not show any effect on fibronectin and tenascin-C protein levels in the presence of 5% FCS 
(Fig. 2C, D). These effects of fluticasone and salmeterol on fibronectin and tenascin-C 
expression were not modulated by further stimulation with TGF-β1 under both 0.3% albumin 
and 5% FCS (Fig. 3). We observed the same results when the primary human lung fibroblasts 
have been treated with other corticosteroids and/or LABAs such as budesonide, formoterol 
(AstraZeneca, Lund, Sweden) or dexamethasone (Calbiochem, Lucerne, Switzerland) (data 
not shown).  
 
 
Modulation of fibronectin and tenascin-C mRNA expression by fluticasone and salmeterol 
So far we investigated the effects of fluticasone and salmeterol alone or in combination on 
fibronectin and tenascin-C protein levels. In order to determine the drug’s effect on 
fibronectin and tenascin-C transcript levels, we performed RT-PCR analysis on mRNA 
isolated from primary human lung fibroblasts cultured under both 0.3% albumin and 5% FCS. 
The agarose gels shown in Figure 4A confirm our immunoblot results. Expression of the 
transcript levels was analyzed by densitometry analysis and normalized to GAPDH and the 
relative gene expression from three cell lines is depicted in Figure 4B. Treatment with 
fluticasone under any experimental condition is associated with a significant increase in 
fibronectin mRNA accumulation (p<0.05), and with a significant reduction in tenascin-C 
transcript levels (p<0.05). On the other hand, administration of salmeterol applied alone or in 
combination with fluticasone did neither modulate fibronectin nor tenascin-C mRNA levels 
compared to controls (Fig. 4B). 
 
To test the modulatory effects of fluticasone and salmeterol on the major splice variants of 
fibronectin and tenascin-C, we specifically designed primers which flank the sequences that 
are subjected to alternative splicing in the human fibronectin and tenascin-C cDNAs (Table 1, 
Fig. 5B top). Treatment with fluticasone in either 0.3% albumin or 5% FCS, but in the 
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absence of TGF-β1 was associated with a down-regulation of the EDA isoform (EDA+) 
compared to non-treated cells, whereas salmeterol did not influence EDA-containing 
transcripts (Fig. 5A). This regulation of the EDA isoform is the exact opposite to total levels 
of fibronectin transcripts. However, in the presence of TGF-β1, the changes in EDA+ mRNA 
expression are masked. The EDB+ isoform is regulated in the same manner as the EDA+ 
transcripts. However, the decrease of EDB+ by fluticasone was also observed in the presence 
of TGF-β1 (Fig. 5A). In contrast to fibronectin, treatment with fluticasone and/or salmeterol 
did not differently modulate tenascin-C isoform expression generated by alternative splicing 
compared to total tenascin-C transcript levels (Fig. 5B, bottom). 
 
Taken together, we show here that fluticasone not only regulate tenascin-C and fibronectin 
protein and mRNA levels in an opposite manner, but also has an opposite effect on total 
fibronectin versus EDA/EDB containing fibronectin isoform expression. This is in contrast to 
salmeterol which has no effect on fibronectin, fibronectin variants or tenascin-C levels under 
any conditions. 
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DISCUSSION 
Asthma and COPD are among the world’s most prevalent diseases. It is estimated that as 
many as 300 million people of all ages and ethnic origins suffer from asthma. Mortality due to 
asthma has now reached over 180 000 cases annually and its incidence is rising by 50% every 
decade, especially among children (National Institutes of Health, 2004). Furthermore, asthma 
is one of the leading causes of hospitalization in young children in industrialized countries. 
Thus, asthma represents a major human and economic burden for the society (Gergen, 2001).  
 
Asthma is more or less effectively controlled in most patients with maintenance treatment. 
Control may be achieved with an inhaled corticosteroid or with a more effective approach of a 
combination inhaler containing a corticosteroid and a LABA. However, their exact 
mechanism of action and direct influence on airway remodeling are not well understood so 
far. 
 
In our report, we studied the effect of fluticasone and salmeterol on tissue remodeling, a 
prominent characteristic of asthma and COPD. More specifically, we analyzed total 
fibronectin, tenascin-C, fibronectin- and tenascin-C isoform secretion by primary human lung 
fibroblasts. Although a recent paper using murine NIH-3T3 fibroblasts showed that 
fluticasone propionate inhibits fibronectin protein as well as mRNA levels (Tomic, Lassiter, 
Ritzenthaler, Rivera, & Roman, 2005), we could not confirm these results in our study. 
Rather, we show that fluticasone as well as other corticosteroids such as budesonide, 
dexamethasone (data not shown) increase fibronectin protein and mRNA levels. This is in 
agreement with other reports showing that corticosteroid treatment is associated with 
fibronectin accumulation (Furcht, Mosher, Wendelschafer-Crabb, Woodbridge, & Foidart, 
1979; Oliver, Newby, Furcht, & Bourgeois, 1983; Talts, Weller, Timpl, Ekblom, & Ekblom, 
1995; Pataki, Madarasz, & Kurucz, 2006). Down-regulation of tenascin-C by corticosteroids 
seems to be common to many cell types as has been shown in several reports (Ekblom, 
Fassler, Tomasini-Johansson, Nilsson, & Ekblom, 1993; Talts, Weller, Timpl, Ekblom, & 
Ekblom, 1995; Fassler, Sasaki, Timpl, Chu, & Werner, 1996; Laitinen et al., 1997; Zhao, 
1999). Interestingly, our results show that even the presence of TGF-β1, an inducer of 
tenascin-C production (Pearson, Pearson, Shibahara, Hofsteenge, & Chiquet-Ehrismann, 
1988; Sakai, Kawakatsu, Ohta, & Saito, 1994) did not counteract the reducing effect of 
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fluticasone on tenascin-C levels. Thus, corticosteroids can down-regulate tenascin-C synthesis 
even in the presence of local stimulatory growth factors. On the other hand, salmeterol did not 
affect fibronectin or tenascin-C levels compared to control, nor did it attenuate the effect of 
fluticasone when applied in combination. This is the opposite of what we found previously for 
total ECM and collagen deposition by lung fibroblasts which was reduced by LABA (Goulet, 
Bihl, Gambazzi, Tamm, & Roth, 2007). 
 
Many reports have shown that applying the current asthma therapy has an impact on airway 
remodeling. Here, we show that two ECM proteins, fibronectin and tenascin-C, are influenced 
in the opposite way by corticosteroids applied alone or in combination. This might have 
functional consequences, since it was shown that fibronectin and tenascin-C can directly 
interact with each other and that presence of tenascin-C results in abolishment of fibronectin-
mediated cell spreading (Chiquet-Ehrismann, Kalla, Pearson, Beck, & Chiquet, 1988; Huang, 
Chiquet-Ehrismann, Moyano, Garcia-Pardo, & Orend, 2001). At least in tumor cells, 
fibronectin and tenascin-C interaction is associated with reduced cell adhesion and enhanced 
cell proliferation (Huang, Chiquet-Ehrismann, Moyano, Garcia-Pardo, & Orend, 2001; Ruiz 
et al., 2004). This might also be true in other pathological conditions such as asthma or 
COPD. Thus, indirect effects of corticosteroids may involve the modulation of cell-cell or 
cell-ECM interactions. In the lungs of asthmatic patients, corticosteroid’s opposite regulation 
of tenascin-C and fibronectin might result in less interaction between the two proteins, which 
could decrease cell proliferation, but strengthen cell adhesion, thus normalizing the 
environment. 
 
Alternative splicing in fibronectin which is dynamically regulated, both temporally and 
spatially, is a very prominent feature of this complex ECM protein (Ffrench-Constant & 
Hynes, 1989). Alternative splicing is clearly adding another level of complexity to the many 
functions ascribed to fibronectin. EDA- and EDB-fibronectin expressions are high during 
embryonic development and basically absent in the adult tissues. However, these extra 
domains get included into fibronectin during pathological conditions such as tumorigenesis, 
inflammation or tissue remodeling (Ffrench-Constant, Van de Water, Dvorak, & Hynes, 
1989). More recently, the discrimination between EDA- and EDB-fibronectin expression in 
pathological conditions and normal tissues was used to specifically target or image sites of 
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tumor angiogenesis or chronic skin inflammation using EDA or EDB-specific human 
monoclonal antibodies (Rybak, Roesli, Kaspar, Villa, & Neri, 2007; Trachsel, Kaspar, Bootz, 
Detmar, & Neri, 2007). Therefore, EDA- and EDB-fibronectin have the potential to be used 
as marker for different pathological conditions such as a vascular marker of solid tumors and 
metastases, a marker for chronic skin inflammation or a marker for atherosclerotic plaques 
(Rybak, Roesli, Kaspar, Villa, & Neri, 2007; Trachsel, Kaspar, Bootz, Detmar, & Neri, 2007; 
von Lukowicz et al., 2007). In our report we show that treatment of primary human lung 
fibroblasts with fluticasone resulted in a down-regulation of EDA- and EDB-fibronectin 
mRNA, while transcript levels of total fibronectin were increased. Thus, EDA- and EDB-
fibronectin show the same response to corticosteroid treatment as tenascin-C, which is the 
opposite to total fibronectin mRNA levels. This represents a further example of the co-
expression of EDA- and EDB-containing fibronectin variants with tenascin-C expression, as 
has been observed during embryogenesis and in cancer. It implies that factors regulating 
alternative splicing of fibronectin seem to be co-regulated with tenascin-C expression. 
Tenascin-C is also subject to alternative splicing (Fig. 1-3). However, we do not have any 
evidence that tenascin-C splice variants are regulated in an opposite manner by corticosteroids 
and LABA compared to total tenascin-C levels as observed for fibronectin splice variants. 
 
In summary, we analyzed the effect of corticosteroids and LABA on the expression levels of 
tenascin-C and fibronectin in primary human lung fibroblasts. Corticosteroid treatment 
negatively regulated expression of tenascin-C. The effect of corticosteroids on fibronectin was 
exactly the opposite: corticosteroids increased fibronectin deposition. LABA neither showed a 
prominent effect on tenascin-C or fibronectin expression nor modulated the effect of 
corticosteroids. However, since we have previously shown that total ECM and collagen 
deposition were decreased by LABA (Goulet, Bihl, Gambazzi, Tamm, & Roth, 2007), it 
becomes clear that the relative prelevance of specific ECM-proteins such as tenascin-C, 
fibronectin and its variants are affected by treatment with corticosteroids as well as LABA. 
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FIGURE CAPTIONS 
Fig. 1. Increased fibronectin and tenascin-C expression by 5% FCS and TGF-β1.  
Confluent serum-deprived primary human lung fibroblasts were stimulated with 5% FCS 
and/or TGF-β1 (2.5 ng/ml) for 48 h. Supernatants were collected and fibronectin and 
tenascin-C were detected by immunoblotting. A representative immunoblot is shown for 
fibronectin (A, top) and for tenascin-C (B, top). Quantification of the immunoblots of three 
different primary cell lines is shown for fibronectin (A, bottom) and tenascin-C (B, bottom).  
Bars represent means ± SEM expressed as % of control, where 0.3% albumin was defined as 
100%. *p<0.05, **p<0.01 and ***p<0.001. The p-values correspond to the comparisons to 
0.3% albumin.  
 
Fig. 2. Fibronectin and tenascin-C regulation by fluticasone and salmeterol. 
Confluent serum-deprived primary human lung fibroblasts were treated with fluticasone (10-7 
M) and/or salmeterol (10-7 M) in 0.3% albumin and 5% FCS for 48 h. Supernatants were 
subjected to immunoblot analysis for fibronectin and tenascin-C. Amido black staining is 
included to show equal protein concentrations. A representative immunoblot is shown for 
fibronectin (A, C, top) and for tenascin-C (B, D, top). The same membrane was used for (A) 
and (B) as well as for (C) and (D). Quantification of the immunoblots of three different 
primary cell lines is shown for fibronectin (A, C, bottom) and tenascin-C (B, D, bottom). Bars 
represent means ± SEM expressed as % of control, where 0.3% albumin and 5% FCS were 
defined as 100%. *p<0.05, **p<0.01 and ***p<0.001. The p-values correspond to the 
comparisons to control.  
 
Fig. 3. Fibronectin and tenascin-C regulation by fluticasone and salmeterol in the 
presence of TGF-β1. 
Confluent serum-deprived primary human lung fibroblasts were treated with fluticasone (10-7 
M) and/or salmeterol (10-7 M) in the presence of TGF-β1 (2.5 ng/ml) in both 0.3% albumin 
and 5% FCS for 48 h. Supernatants were subjected to immunoblot analysis for fibronectin and 
tenascin-C. Amido black staining is included to show equal protein concentrations. A 
representative immunoblot is shown for fibronectin (A, C, top) and for tenascin-C (B, D, top). 
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The same membrane was used for (A) and (B) as well as for (C) and (D). Quantification of 
the immunoblots of three different primary cell lines is shown for fibronectin (A, C, bottom) 
and tenascin-C (B, D, bottom). Bars represent means ± SEM expressed as % of control, where 
0.3% albumin and 5% FCS were defined as 100%. *p<0.05, **p<0.01 and ***p<0.001. The 
p-values correspond to the comparisons to control. 
 
Fig. 4. Modulation of fibronectin and tenascin-C mRNA expression by fluticasone and 
salmeterol. 
Confluent serum-deprived primary human lung fibroblasts were treated with fluticasone 
and/or salmeterol (10-7 M) in the absence or presence of TGF-β1 (2.5 ng/ml) under both 0.3% 
albumin and 5% FCS. Total RNA was extracted after 48 h and cDNA was synthesized. 
Representative PCR gels are shown in (A) and quantification of three cell lines is shown in 
(B). Bars represent means ± SEM expressed as fold induction compared to control and are 
normalized to GAPDH. *p<0.05, **p<0.01 and ***p<0.001. The p-values correspond to the 
comparisons to 0.3% control.  
 
Fig. 5. Modulation of fibronectin and tenascin-C isoform mRNA expression by 
fluticasone and salmeterol. 
Confluent serum-deprived primary human lung fibroblasts were treated with fluticasone 
and/or salmeterol (10-7 M) in the absence or presence of TGF-β1 (2.5 ng/ml) under both 0.3% 
albumin and 5% FCS. Total RNA was extracted after 48 h and cDNA was synthesized. (A) 
Representative PCR gels of the major fibronectin splice variants, where EDA+ and EDB+ 
indicate the EDA-containing fibronectin, or the EDB-containing firbronectin isoform 
respectively are shown. (B) Schematic representation of the 15 fibronectin type III repeats 
(white boxes: constant repeats; grey boxes: repeats subject to alternative splicing) present in 
tenascin-C and the primers used to detect the tenascin-C isoforms is shown (top). 
Representative PCR gels of the tenascin-C splice variants are shown (bottom). Seven TN-C 
isforms are detectable corresponding to the inclusion of the seven fibronectin type III repeats 
(grey boxes, top), each containing 276 bp. The major isoforms present in the primary human 
lung fibroblasts are highlighted by asterisks (*, **) and they give rise to the 250 kDa and 180 
kDa protein respectively. 
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III.3 Unpublished Results 
III.3.1 Tenascin-W detection in human serum 
In collaboration with Curzio Rüegg, Division of Experimental Oncology, Centre Pluridisciplinaire d’Oncologie, 
and Swiss Institute for Experimental Cancer Research (ISREC), NCCR Molecular Oncology, Epalinges, 
Switzerland. 
 
After having established a sensitive sandwich-ELISA assay, we measured TN-W serum levels 
in 16 non-metastatic (at time of diagnosis) breast cancer patients, in 17 non-metastatic colon 
cancer patients and in 25 healthy volunteers. Serum before and 6 weeks after surgical tumor 
resection was available for each patient. The mean TN-W value of control sera was 0.389 +/- 
0.14 mg/l (Fig.III.1A). In sera of breast cancer patients before surgery we measured an 
elevated mean TN-W level of 0.682 +/- 0.44 mg/l which corresponds to a 1.75-fold increase 
compared to control. However, the mean TN-W level in the same breast cancer patients six 
weeks after surgical tumor removals did not significantly decrease (0.631 +/- 0.45 mg/l) 
(Fig.III.1B). Details about the serum TN-W levels in breast cancer patients are given in table 
III.I. 
 
 
 
 
 
 
 
 
 
 
Figure III.1: Tenascin-W in sera of breast cancer patients 
Histograms comparing the serum TN-W levels in healthy volunteers (n=25), breast cancer patients (n=16) before 
and after tumor removal. Mean TN-W levels: healthy individuals: 0.389 +/- 0.14 mg/l; breast cancer before 
surgery: 0.682 +/- 0.44 mg/l; breast cancer after surgery: 0.631 +/- 0.45 mg/l.  
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Table III.I: Tenascin-W levels in breast cancer serum 
 
 
 
 
 
 
 
 
 
 
TNW: protein levels in serum deduced by sandwich-ELISA 
 
Serum TN-W concentrations in non-metastatic colon cancer patients were significantly 
elevated compared to those in healthy volunteers (p<0.005) with a mean level of 0.794 +/- 
0.38 mg/l (Fig.III.2A). This corresponds to a 2.04-fold increase in comparison to healthy 
individuals. Furthermore, we observed a reduction of the mean TN-W level in sera 6 weeks 
after tumor removal compared to the levels before (Fig.III.2A). However, not every patient 
followed this tendency. For some patients we monitored even increased TN-W levels after 
surgical tumor resection (Table III.II). 
 
Since TN-C was shown to be elevated but scattered over a wide range in serum of patients 
suffering from different tumors [104-106, 143-146], we also monitored TN-C serum levels in 
the same cohort of colon cancer patients. We wanted to test whether TN-W might have a 
higher sensitivity for cancer detection than TN-C. In the few control samples that were 
available (n=13), we measured a mean TN-C level of 0.775 +/- 0.25 mg/l (Fig.III.2B), which 
is approximately twice as high as the control level of TN-W and which nicely fits to the 
literature [147]. The colon cancer patients showed elevated TN-C levels (mean: 0.98 +/- 0.26 
mg/l) which is in agreement with the literature [144-146]. However, the increase (1.26-fold) 
was not as pronounced as that of TN-W. Mean concentration in serum after tumor resection 
only slightly decreased (0.902 +/- 0.23 mg/l), but did not reach the control value (Fig.III.2B). 
Similar to TN-W, some patient had even higher TN-C levels after tumor removal (Table 
III.II). 
Patient TNW (mg/l) TNW (mg/l)
before after
18 0.243 0.389
19 0.150 0.280
20 0.211 0.211
21 0.157 0.156
22 0.672 0.726
23 0.582 0.393
24 0.582 0.372
25 0.259 0.431
31 0.949 0.676
33 0.459 0.286
34 0.923 0.765
36 1.580 1.940
37 1.290 1.050
38 0.745 0.540
40 0.880 0.785
42 1.230 1.100
average 0.682 +/- 0.44 0.631 +/- 0.45
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Figure III.2: Comparison between serum tenascin-W and tenascin-C levels in colon cancer patients 
(A) Histograms of TN-W levels in colon cancer show a prominent increase (p<0.05) compared to them in 
volunteers. After tumor removal, TN-W levels slightly decreased (p=0.348). (B) Same tendency is true for TN-C 
however the increase in the colon cancer samples is more moderate. 
 
 
Table III.II: Tenascin-W and tenascin-C levels in colon cancer serum before 
and 6 weeks after tumor removal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TNW, TNC: protein levels in serum deduced by sandwich-ELISA 
Patient TNW (mg/l) TNW (mg/l) TNC (mg/l) TNC (mg/l)
before after before after
27 0.380 0.160 0.760 0.776
28 0.330 0.410 0.810 0.758
29 0.382 0.218 1.080 0.764
31 0.949 0.676 n.d. n.d.
32 0.560 0.329 0.674 0.523
35 1.100 0.892 0.920 0.722
39 0.800 0.728 0.848 0.724
41 1.230 1.400 0.984 0.952
49 0.500 0.397 0.674 0.785
50 0.473 0.531 0.571 0.826
51 1.400 0.982 1.150 0.799
52 1.130 0.890 0.733 0.715
53 1.380 1.050 1.240 0.967
54 0.920 0.842 1.090 1.170
55 1.270 0.735 0.908 1.270
56 0.560 0.824 0.915 1.060
57 0.563 0.527 1.620 1.270
58 0.520 0.914 1.280 1.310
average 0.794 +/- 0.38 0.696 +/- 0.33 0.98 +/- 0.26 0.902 +/- 0.23
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Immunoprecipitation (IP) followed by immunoblotting of three different serum samples 
(control, colon cancer, and breast cancer) resulted in the detection of a single TN-W-specific 
band, corresponding to the size of the purified full-length TN-W (Fig.III.3). This indicated 
that we were measuring the intact mature TN-W protein in serum. Furthermore, we could 
confirm the tendency of TN-W towards higher expression in serum of colon cancer patients 
compared to control and breast cancer serum. Densitometric analysis (Fig.III.3, bottom) 
revealed a 1.9-fold increase in TN-W concentration in the colon cancer sample which nicely 
fits to the monitored increase by our sandwich-ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.3: Tenascin-W detection in serum by IP/western blot analysis 
IP followed by western blot analysis reveals increased TN-W levels in colon cancer serum compared to the 
levels in control and breast cancer serum. Shown are the immunoblot (top) and the densitometric analysis 
(bottom). 
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In a last set of experiments with respect to serum tenascin levels, we analyzed TN-W and TN-
C levels in serum from five melanoma patients. These patients have been treated with very 
high doses of TNFα and mephalan, a combination that was administered through isolated limb 
perfusion (ILP) [148-150]. Since TN-W was shown to be induced by TNFα [151], we were 
interested to measure serum TN-W levels in these patients at different time-points after ILP 
treatment (Table III.III). 
 
 
Table III.III: TNW and TNC in sera of melanoma patients treated with ILP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNW, TNC: protein levels in serum deduced by sandwich-ELISA 
 
 
In all five melanoma patients we could detect prominently elevated serum TN-W as well as 
TN-C levels compared to that in healthy volunteers (Fig.III.2). Furthermore, all patients 
showed high TN-W levels at the early time-points (0, 2 hrs), which then transiently decreased, 
but finally increased again at later time-points after ILP. Except for patient 5 which showed 
highest TN-W concentration at time-point 0 hrs (patterned bar in Fig.III.4), all other patients 
displayed highest values for TN-W at late time-points. In contrast to TN-W, TN-C levels 
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mostly showed a steady increase with time reaching a maximum at late time-points. In 
general, we could not find any simple correlation between TN-C and TN-W levels in these 
patients, but observed a different response of the two tenascins to this ILP treatment 
(Fig.III.4). 
 
 
 
 
Figure III.4: Detection of tenascin-W and tenascin-W in ILP-treated patients 
Patients were treated with high doses of TNFα in combination with Mephalan and their serum was collected at 
the indicated time points after ILP treatment and later analyzed by sandwich-ELISA. TN-W and TN-C show a 
different response to this treatment. Generally, TN-C levels are increasing with time, whereas TN-W levels are 
high at the beginning, followed by a decrease, but finally increase again. Highest tenascin concentration 
(patterend bar) was set to 100 % and all other concentrations are displayed relative to this maximal value. 
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III.3.2 Tenascin-W expression in cell cultures and tissues 
III.3.2.1 Cell culture studies 
Since no studies existed about human TN-W, we decided to analyze endogenous TN-W 
expression in human cell lines. Under standard cell culture conditions TN-W expression was 
detected in mouse embryonic fibroblasts (MEFs) only [151]. Its expression could be induced 
by bone morphogenetic protein 2 (BMP2) in C2C12, 4T1 cells and MEFs, and by TNFα in 
MEFs [56, 151]. These results together with the stromal staining patterns obtained by 
immunohistochemistry suggested stromal fibroblasts as cellular source for TN-W. Therefore 
we analyzed endogenous TN-W and TN-C expression in three different human fibroblast 
lines: Detroit 551 (skin), MRC5 (lung), and IMR90 (lung). We cultured them to a confluency 
of about 70 % in normal culture medium, switched them to starvation medium (1 % FCS) and 
added the indicated growth factors for another 72 hours. 500 μl of the cell supernatants of 
each condition was then subjected to IP followed by immunoblot analysis. As a positive 
control, we added 10 ng of purified TN-W to 500 μl medium. Immunoblots revealed that none 
of the fibroblasts under any condition expressed TN-W at detectable levels (Fig.III.5A). In 
contrast to TN-W, TN-C was expressed endogenously in all three fibroblasts (Fig.III.5B, PBS 
sample). Addition of growth factors was able to induce TN-C expression to different extents 
as indicated by the densitometric analyses (Fig.III.5B, bottom). There was a cell type-specific 
response to the stimuli. Nevertheless, in all three cell lines, TGFβ and TNFα were the most 
potent inducers for TN-C expression. 
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Figure III.5: Endogenous tenascin-W and tenascin-C expression in fibroblasts 
Three different human fibroblasts lines were treated with different growth factors and their supernatants were 
analyzed for TN-W (A) and TN-C (B) presence by immunoblotting. TN-C blots were further quantified by 
densitometric analyses (B, bottom). Concentrations of the growth factors used: TGFβ: 5 ng/ml; TNFα: 20 ng/ml; 
BMP2: 100 ng/ml; FGF2: 10 ng/ml. 
 
 
Some reports indicate epithelial cancer cells as a potential source for TN-C production [152-
154]. To test whether epithelial cancer cells could be a source for TN-W expression in tumors 
as well, we analyzed its production in different breast cancer cell lines (MDA-MB-435, 
MCF7, T47D). Breast cancer cells were chosen since we observed prominent TN-W presence 
in a different cohort of breast tumor patients by immunoblotting and immunohistochemistry. 
Cells were treated, and their supernatants analyzed as described before for fibroblasts. None 
of these cell lines tested expressed TN-W (Fig.III.6A, only the MDA-MB-435 cell line is 
shown) and only the MDA-MB-435 cell line produced endogenous TN-C (Fig.III.6B, PBS 
sample). TN-C expression could be further induced by addition of specific growth factors 
(Fig.III.6B). This was in contrast to TN-W (Fig.III.6A) whose expression could not be 
induced by any growth factor. 
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Figure III. 6: Endogenous tenascin-W and tenascin-C expression in breast cancer cells 
MDA-MB-435 cells were treated with different growth factors and their supernatants were analyzed for TN-W 
(A) and TN-C (B) presence by immunoblotting. 
 
 
 
 
Our own immunohistochemical studies as well as the literature revealed TN-W and TN-C 
expression in the activated tumor stroma [9, 151]. As described in the “Introduction”, an 
activated stroma arises as a result of a complex cross-talk between epithelial and stromal cells 
[14, 16, 17, 20, 23]. Therefore, we tested whether we could induce TN-W expression by 
mimicking this in vivo situation in vitro. For that reason we performed co-culture assays. We 
cultured epithelial breast cancer cells together with fibroblasts for 72 hours, collected the 
conditioned medium and analyzed the medium by immunoblot analysis. However, we were 
not able to detect endogenous TN-W in these co-cultures either (data not shown). 
 
To test several cell lines for the presence of TN-W mRNA, we performed RT PCR of 16 
different cancer cell lines. With the primer pair 5’–AAATACAGAGGCACGGCAGG–3’ / 
5’– GTCCTTTCCAAGGCTCCCA – 3’ a TN-W-specific fragment of 212 bp was amplified. 
In all cell lines tested a specific band of the expected size was detectable (Fig.III.7). This 
indicated that TN-W mRNA is present in all cell lines tested. Although mRNA was 
detectable, we were not able to detect the endogenous protein in the corresponding cell lines. 
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Figure III.7: Tenascin-W mRNA in different human cell lines 
RT PCR of 16 different human cell lines reveals presence of TN-W mRNA in every cell line. 
III.3.2.2 Tissue studies 
In collaboration with Luigi Terracciano, Institute of Pathology, University of Basel, Basel, Switzerland 
 
In order to analyze the endogenous TN-W expression in different adult tissues, we performed 
immunoblots of ten different normal organ extracts (Fig.III.8A). In the spleen and liver 
extracts a small amount of TN-W could be detected, whereas all other normal tissues tested 
were negative for TN-W. The same blots were probed with a monoclonal anti-TN-C antibody 
and revealed basal TN-C expression in all tissues, except for breast and heart. In pancreas, 
kidney and colon extracts only the low molecular-weight isoform of TN-C was produced 
(Fig.III.8A). To test whether TN-C shares its prominent expression in tumors with TN-W, we 
analyzed human extracts from pancreas (9 patients) and kidney (9 patients) tumors 
(Fig.III.8B).  As expected, we detected TN-C expression in 7/9 (78 %) kidney cancer patients 
and 5/9 (56 %) pancreas cancer patients. Not only TN-C was highly up-regulated in these 
cancer tissue extracts, but also TN-W. 6/9 (67 %) kidney cancer samples and 7/9 (78 %) 
pancreas cancer samples were positive for TN-W. Similar to our previous findings in breast 
and colon cancer tissue extracts, there is great variance in the tenascin amounts produced in 
the different pancreas and kidney tumor extracts.  
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Figure III.8: Tenascin-W expression in normal and tumor tissues 
(A) Western blot of ten normal adult tissues reveals low TN-W levels in spleen and liver, while all the other 
tissues tested are TN-W negative. In contrast, there is basal TN-C expression in the majority of the normal 
tissues tested. (B) In pancreas and kidney cancer patients, TN-W as well as TN-C are highly up-regulated. 
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III.3.3 Structure of the human tenascin-W gene and functional 
characterization of the promoter 
Rapid amplification of cDNA ends (RACE) was performed to define and identify the 5’ end 
of the human TN-W transcript. No band was detected on the agarose gel after the first PCR 
with the adapter specific outer primer (oligo dT-anchor primer) and the gene specific reverse 
primer hSP2 (Fig.III.8A; see appendix for primer sequences). However, after the second PCR 
with the adapter specific inner primer (PCR anchor primer) and the gene specific reverse 
primer hSP3 a band was detected on the gel (Fig.III.8A). Sequencing revealed that this 
fragment corresponded to the ATG-containing exon and a non-translated exon 1 of the human 
TN-W gene containing 78 bp (Fig.III.8B). Therefore, the most 5’- reaching cDNA was 
identified 128 bp from the translational start site present in exon 2. In the genomic DNA exon 
1 is located 9448 bp upstream of exon 2 (Fig.III.9/10). Our experimental finding was 
confirmed by different database gene predictions (e.g.: www.ensemble.org). 
 
A     B 
 
 
 
 
 
 
 
 
 
Figure III.8: 5’ RACE 
(A) 5’RACE PCR. 15 μl of the 25 μl PCR was separated on a 1.5% agarose gel. One microliter of the first PCR 
was used as template for the second PCR. Sample: 5’RACE probe. (B) Sequence of the first non-coding exon 
(black box) as found in the 5’RACE is shown. It contains 78 bp. Grey box indicates the second exon containing 
the translation initiation site (shown in black font). Black box shows the first non-translated exon of TN-W. 
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The human TN-W gene consists of a total of 19 exons spanning 80 kb of genomic DNA 
(Fig.III.9). The transcript starts with a non-coding exon followed by exon 2, which contains 
the start codon (ATG) for translation initiation. 
 
Figure III.9: Genomic organization of the human tenascin-W gene 
The distribution of the 19 exons is shown in the upper part, whereas the lengths of exons and introns are 
indicated in the lower part.  
 
 
Analysis of the genomic sequences of TN-W orthologs revealed conserved presence of a first 
non-coding exon upstream of the ATG-containing exon (Fig.III.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.10: Genomic distribution of the first two exons in the tenascin-W gene 
Genomic distribution of the first two exons in different TN-W orthologs is shown. Non-translated regions are 
indicated in black. h: human; m: mouse; z: zebra fish 
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Sequence alignments [155] of the putative promoters of the human and mouse TN-W genes 
500 bp upstream of the first exon and of exon 1 revealed a very high similarity as indicated by 
the black and yellow boxes (Fig.III.11).  
 
 
 
 
 
 
   hTNW-500 TCCTGC-------------CA---C-TCACAAGTGTGAGACGATGGATGAAGGAGGAGGG 
   mTNW     TCCTCAGCCCTATTCAGAGCCTTGCCTCTCACCTGTCAGGTGATGGA-GAAGGAGATGGG 
 
   hTNW AAGTCAG--AAGAGCTTCTG--TCCCTGAGGGTC-TCTGCTCATTTCTTTCTGTGCTAAA 
   mTNW     AGATGGGTCAA-AGC-AGGGATTCCCTTGGGGGCCTCT-CTGACTTC-TT-T---CT--- 
 
   hTNW GGCTTTTTCCCATTTTAAAAGCAGTAGGCAGGAAGTCCCAGAATGCCTGAAACAGGAAAA 
   mTNW ---T-------ATTTTAGGAGGAGTAAGCAGCAAGTTCCAGAATGTCTGGAACATGAAAA 
 
   hTNW     AGAGAAAGAAACTTTATAAATGCACTTTTGAACCCCGAGACCCAGCTCCTGGCCAGGAGA 
   mTNW     AGAG------ACTTAATAAATACAC-TTTCAAACCCGAGACTCAGCTCCTGGCCAGGAGA 
 
   hTNW     CAGGCAAACTCTTTTAATATCCTTATTCTGGATTCACTTAAATGGAAACAGCCTCCAGTA 
   mTNW     CATGCAAAC-GTTTTAATATCCTTGTTCTGCATTTACTTAAATGGAAACAGCCCGTGGTA 
 
   hTNW     TTTTTAGCTGCTGTGTAATCAAAGTGAAAAAGAAGAAGGAAATGTATA-TATTTTTC-TT 
   mTNW     TTTTTAGCTGCTGTGTAATCAACGT-AAGAAGGAAAGGGGAATGTATACTTTTTTTCCTT 
 
   hTNW     -TCCTAGTTAGAATAAGAGAAGGAATTGCTCATTATCTTTTAGCAGAGTCCCTGCTAGGA 
   mTNW     CTCCTAGTTAGAGTAAGAGAATGAATTGCTCA--AT-TCTCAACAGAGTCC-----AGGA 
 
   hTNW     AGGGAGGAAAACACCAGGAGTCTCCAT--TTG-CTCCTCCTCTGGCCTAGACAGGATTTA 
   mTNW     AGGGAGGAAAAT-CCCGGAGTCCCATTGATTGGCTCCTCCTCTGTCATAGCCTTGATTTA 
 
   hTNW     AACCCAGGAAGGGAAGCCAAGGAGAGACGAGAACCAGGGACG-ACC---A-—G------- 
   mTNW     AACCCAGGGAGGGAAGCAGAGG-GAGAAGATATTGAGGGACGGATCGGCAACGAAGTCTC 
 
   hTNW -1  CAAGTACCAAGGTCTGCGGCAGGAGGAGACCGGCTCACAGGAG-CAGCAGCATTGGAAGA 
   mTNW     C-AGTACCA-----------------GGACCAGCTCACAGGAGGCAGGGGGATTGGAAGT 
 
   hTNW 59  GGCACCCAGCAGCCTCCCAG 
   mTNW     GGTGCCCAGCAGCCTCCCAG 
 
 
 
 
Figure III.11: Sequence alignment of the tenascin-W promoter regions 
Sequence alignment of the 500 bp upstream of the first exon (black boxes) and of the first exon (yellow boxes) 
between mouse and human tenascin-W is shown.  
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To investigate the functionality of the TN-W promoter, we cloned different luciferase 
promoter constructs, all containing exon 1 and different lengths of the 5’ flanking region 
(Fig.III.12A). To compare promoter activity of TN-W with that of TN-C, we cloned three 
TN-C luciferase constructs as well (Fig.III.12B).   
 
 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure III.12: Luciferase constructs  
Shown are the TN-W (A) and TN-C (B) promoter constructs containing different lengths of the putative 
promoter regions that have been cloned in front of the luciferase gene present in the pGL3-basic vector. 
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This allowed a direct comparison between the regulatory mechanisms and the promoter 
strengths of TN-W and TN-C. The promoter constructs together with the β-Gal expression 
plasmid as internal standard for transfection efficiency were transiently transfected into 
different human cell lines. In a first try, we tested whether we get any luciferase activity with 
the TN-W specific constructs 4kb, 2kb, 1kb, 500bp and compared it to the activity obtained 
by either transfecting the empty pGL3-basic vector (negative control) or a SV40 promoter-
containing expression vector (positive control). Indeed, in HT1080 (fibrosarcoma) as well as 
in Saos2 cells (osteosarcoma) all the promoter-containing luciferase constructs showed clear 
luciferase induction as compared to the negative control (Fig.III.13/14). Highest luciferase 
activity was obtained with the shortest (500 bp) construct in both cell lines (Fig.III.13/14) and 
reached about half the activity obtained by the strong SV40 promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.13: Luciferase assay in HT1080 cells 
Luciferase activity of different TN-W promoter constructs in HT1080 cells compared to a negative control 
(basic) and a positive control (SV40). Graph represents three independent experiments. 
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Figure III.14: Luciferase assays in Saos2 cells 
Luciferase activity of different TN-W promoter constructs in Saos2 cells compared to a negative control (basic) 
and a positive control (SV40). Graph represents three independent experiments. 
 
 
 
 
 
To identify the promoter regions important for transcription regulation, the constructs were 
further truncated. Figure III.15 shows that shortening the construct to 250 bp still gave 
optimal activity. Interestingly, there was still some activity in a construct containing the 
sequence of exon 1 only (Fig.III.15). This implies that the non-translated first exon contains 
regulatory elements as well. Furthermore, this study revealed that the TN-C promoter activity 
was equally strong as SV40 and about 2-fold stronger than that of TN-W (Fig.III.15). TN-C 
promoter activity was found to be highest in the 260 bp construct which is in agreement with 
previous publications [156]. 
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Figure III.15: Luciferase assay in HT1080 cells including TN-C constructs 
Luciferase activity of TN-W promoter constructs in HT1080 cells compared to a negative control (basic) and a 
positive control (SV40). Graph represents three independent experiments. 
 
 
 
Since we found highest TN-W promoter activity in the 250 bp construct, the first 250 bp 
upstream must contain important sites for TN-W gene regulation. Therefore, we performed 
transcription binding site predictions within these 250 bp using ConSite. Potential 
transcription factor binding sites, which are conserved between human and mouse TN-W, are 
shown in Figure III.16.    
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Figure III.16: Potential transcription factor sites in the first 250 bp 
The potential transcription factor binding sites, which are conserved between mouse TN-W (green) and human 
TN-W (blue), are shown (top). Their specific binding motifs as well as their exact positions are indicated in the 
table (bottom). 
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IV. Discussion  
This thesis is the result of a joint effort including many collaborators contributing materials, 
suggestions and ideas. Therefore, the discussion refers to “our” results. 
IV.1 Our ambition 
More than two decades ago, TN-C was identified as an ECM protein enriched in the stroma of 
gliomas [87] and as a myotendinous antigen [88]. The results of intensive studies on its role in 
cell and developmental biology as well as in different pathologies together with its high 
conservation in every vertebrate species [166] suggested a fundamentally important function 
for TN-C. Therefore, it was a huge surprise and disappointment to see that mice develop 
normally without TN-C [167]. Knock-out technology had not only failed to elucidate the 
function of TN-C, but it pointed to a redundant role for this protein [168]. However, this 
shock challenged people in the tenascin field to perform more thorough investigations. And 
upon more detailed inspection of the TN-C-deficient mice, more and more abnormalities 
appeared ranging from defects in behavior to impaired angiogenesis and deficiencies in stem 
cells (reviewed in [96]). In the meantime, three new tenascins have been discovered (for 
reviews see [9, 51]), the last one being TN-W [141]. TN-W represents the final member of the 
tenascin family.  
 
TN-W was originally identified in zebra fish where it is co-expressed with TN-C by neural 
crest cells and somites [141]. More recently, murine TN-W was characterized and 
immunohistochemistry revealed prominent expression in the developing and adult kidney, 
developing and adult bone, and transiently in smooth muscle cells [56]. Despite the tight 
spatio-temporal regulation, a prominent feature common to all tenascins [58], TN-W 
expression often completely or at least partially overlapped with that of TN-C [56, 141, 151, 
169]. Since TN-C is prominently and specifically expressed in the tumor stroma of a variety 
of cancers [9], it was evident to start studying TN-W expression and function in tumors. 
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Initially we studied TN-W function in murine tumor models, but then decided to switch to 
human TN-W which might be more relevant and of higher general interest. Our goal was to 
clone the gene, characterize the protein, and investigate its expression, its functions, and its 
involvement in tumor malignancies and compare it to TN-C, a known marker for activated 
tumor stroma [9]. 
 
Furthermore, we started collaborations to identify and describe new aspects of TN-C 
regulation during different human pathologies.  
IV.2 Tenascin-W in the context of tumors 
First data linking TN-W to the presence of tumor malignancies were obtained in mice [151]. 
Oncogene-induced mammary tumor models suggested that TN-W was preferentially 
expressed in primary tumors with the highest potential to metastasize. TN-W specifically 
localized to the tumor stroma, where it was, at least partially, co-localized with TN-C. In 
addition, its putative integrin receptor α8β1 [56] showed a similar tendency: its expression 
increased with the malignancy of a tumor. Functional studies revealed that TN-W can support 
migration of breast cancer cells in vitro, but not of normal mammary epithelial cells. 
Therefore, we proposed a model where presence of TN-W in the tumor stroma promotes 
motility of cancer cells expressing α8 integrin. Thereby TN-W contributes to the metastatic 
potential of cancers. Of course if these findings would hold true in human tumors, TN-W 
could have great potential as a diagnostic tool as well as a potential stromal target for cancer 
therapy. 
 
Here, we have presented our first results on human TN-W. We investigated its function and 
determined its expression in tumors. For the expression analysis, we tested in total 97 
different tumor tissue extracts (63 breast cancers, 9 kidney cancers, 9 pancreas cancers, and 
16 colon cancers) for the presence of TN-W and TN-C. Out of these 97 different cancer 
tissues, 77 % (75/97) showed a prominent up-regulation of TN-W and 82 % (80/92) were TN-
C positive (Table IV.I).  
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Table IV.I: Summary of TN-W and TN-C expression in tumors 
 
 
 
 
 
 
 
 
Despite the fact that a majority of the tested tumor extracts showed expression of TN-W and 
TN-C, their amounts differed greatly between patients. This implied independent regulation of 
their expression. Normal tissue was negative for TN-W, except for a slight expression in 
spleen and liver. This was in contrast to TN-C which showed basal expression in all tissues 
tested, except in breast and heart. For most of the 63 breast cancer extracts the 
clinicopathological features of the patients were available and we could correlate TN-W 
expression with tumor grade. We found a statistically significant enrichment of TN-W in low-
grade breast tumors (G1/G2) although there were also high-grade (G3) patients having high 
TN-W levels and vice versa. But the mean value of TN-W in low-grade tumors was higher 
than that in high-grade tumors. This was in contrast to TN-C, whose expression could not be 
correlated with tumor grade in mammary tumors. This is in agreement with previous reports 
on TN-C in breast cancer, which showed no clear correlation between TN-C and patient 
prognosis. However, in other tumors such as in lung, colon and brain tumors, TN-C 
expression correlates with poor patient prognosis [95]. Although tenascins are known to be 
subject to alternative splicing [59], we do not have any evidence for the existence of TN-W 
splice variants. We always obtained a single band by immunoblot analysis of the different 
tissue extracts. However, we observed differential expression of TN-C isoforms in the 
different cancer patients. Although there is one report showing that some specific TN-C 
isoforms are only expressed in invasive breast carcinomas [101], we were not able to confirm 
this finding in our 63 breast cancer extracts.  
 
In agreement with our findings, TN-W enrichment in low-grade breast cancer was 
independently confirmed in a different patient cohort by RNA profiling of breast cancer 
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patients [170]. This data set showed a good correlation between TN-W transcript levels and 
tumor grade. These results are accessible in the ONCOMINE database [171]. This correlation 
is probably tissue-specific since RNA profiling of prostate cancer patients in a different study 
revealed higher TN-W expression in metastasizing prostate carcinomas (high-grade) and 
lower expression in benign prostate tumors [172]. The opposite was the case for TN-C which 
displayed highest transcript levels in benign prostate tumors and lowest in metastasiszing 
cancers. It seems that at least in prostate cancer the two tenascins are expressed directly 
reverse to each other [172], which implies that they might have different functions during 
tumor progression. Experimental evidence for these observations in a different cohort of 
prostate cancer patients is lacking, but it seems likely that TN-W shows tissue specific 
expression and functions. 
 
In tumor tissues expressing TN-W and TN-C, immunohistochemistry mostly revealed co-
localization of the two proteins in the tumor stroma. TN-W was exclusively localized to the 
tumor stroma, whereas some rare tumors revealed TN-C expression in the epithelial 
compartment as well. Breast tumors with epithelial TN-C expression all belonged to high-
grade (G3) tumors. This might suggest that initially, activated stromal fibroblasts are the 
cellular source for TN-C expression. However, during tumor progression, stromal cell-derived 
factors acting in a paracrine fashion to the epithelium induce synthesis of TN-C in the 
transformed epithelial cells. This would be in agreement with previous reports showing TN-C 
expression in certain cancerous epithelial cells [152-154]. Further evidence for our suggestion 
could be the fact that the highly aggressive breast cancer cell line MDA-MB-435 produces 
high amounts of TN-C, whereas the less-invasive MCF-7 and T47D breast cancer cell lines 
[173] do not express it (own observations). So far we can only speculate what the cellular 
source of TN-W is. We hypothesize that activated stromal fibroblasts produce and secrete 
TN-W. However we cannot exclude contribution of the transformed epithelium to TN-W 
deposition in the stroma. At least in mouse cells we could induce endogenous TN-W in MEFs 
and in 4T1 epithelial breast cancer cells by TNFα, exemplifying the two potential distinct 
cellular sources for TN-W. 
 
For 11 breast cancer patients, follow-up data was available. Four out of these 11 patients 
showed tumor recurrence. Strikingly, we measured very high TN-C levels in the primary 
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tumor extracts of the corresponding patients by immunoblot analysis. This could indicate that 
high TN-C levels could identify those patients having higher probability to develop recurrent 
tumors. For TN-W, we could not observe a clear correlation between tumor relapse and high 
protein levels. 
 
Co-localization of TN-W and TN-C in the activated tumor stroma in breast cancer suggested 
similar but not necessarily identical functions. We observed a similar effect of the two 
tenascins on adhesion when offered as single substratum to breast cancer cells: cells are not 
able to attach to and spread on tenascins. However, in contrast to TN-C, TN-W mixed with 
fibronectin did not abolish fibronectin-mediated cell-spreading. Furthermore, fibroblasts were 
able to attach to and partially spread on TN-W under conditions where they remained round 
on TN-C. Fibroblasts on TN-W changed their morphology, forming long actin-rich processes, 
and appeared much more contracted than the same cells plated on fibronectin. This 
morphology somehow resembled that described for CAFs [19]. Therefore, it would be 
interesting to know whether CAF’s also show such adhesive properties on a TN-W 
substratum. Concerning the process of migration, TN-W and TN-C share the property of 
inducing cancer cell migration on an adhesion-mediating substratum such as fibronectin or 
type I collagen when added exogenously to the medium. 
 
Taken together, our results imply an active role for TN-W in the process of tumor progression 
by influencing cancer cell and stromal cell behavior. We suggest the following model for TN-
W action (Fig.IV.1): neoplastic epithelial cells alter their adjacent stroma by secreting soluble 
growth factors, cytokines or chemokines. As a response to the tumor-cell-derived factors, 
stromal cells are activated and they start to modulate their microenvironment by secreting 
autocrine as well as paracrine effector molecules. Among many others, they specifically 
produce TN-W and TN-C, which in combination with other ECM molecules influence cancer 
cell and stromal cell behavior. 
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Figure IV.1: Model for tenascin-W action 
Transformed epithelial cells (blue) secrete paracrine growth factors to the stromal fibroblast (green). As a 
response to these tumor cell-derived factors, fibroblasts are activated and change their expression profile. Among 
other effector molecules, TN-C and TN-W are produced. TN-W and TN-C in combination with other ECM 
molecules serve as a pro-migratory environment for cancer cells. Alternatively, cancer cell may be a source for 
TN-C and TN-W production themselves, thereby establishing their preferred, migration-facilitating environment. 
BM: basement membrane; ECM: extracellular matrix. 
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IV.3 Significance of tenascin-W as tumor marker 
Up to now, we have discussed the fact that TN-W is highly expressed in a large fraction of 
different cancer patients, and that normal adult tissues do not show detectable TN-W levels. 
This implies that TN-W might have the potential to serve as tumor marker, since a clear 
difference between healthy and diseased tissue is a prerequisite for any biomarker. TN-C, 
which shows a similar expression pattern as TN-W, has been extensively analyzed in sera of 
different cancer patients and evaluated for its significance to act as tumor marker [104, 105, 
143-145]. Most of the reports indicate increased TN-C serum levels in cancer patients. 
However, the values are usually scattered over a wide range, including cancer patients having 
normal TN-C levels. Hence, TN-C still remains a questionable tumor marker [104]. A further 
problem is that TN-C is not solely linked to neoplasms, but also to infections and 
inflammations [9]. Thus, a large fraction of TN-C in the serum could derive from such 
inflammatory pathological conditions rather than from the tumor mass.  
 
In search for new diagnostic tumor markers, we monitored TN-W serum levels in cancer 
patients by a sensitive sandwich-ELISA assay. In the cohort of non-metastatic colon cancer as 
well as in the cohort of non-metastatic breast cancer patients we could detect a significant 
increase in mean TN-W levels compared to control. In sera of colorectal cancer patients we 
measured a 2.04-fold increase, whereas a 1.75-fold elevation could be detected in sera of 
breast cancer patients compared to volunteers. A useful tumor marker would have elevated 
levels at the time of diagnosis and reduced levels after tumor resection or during cancer 
treatment. This would allow to follow-up cancer patients after their therapy and the detection 
of a later potential recurrence as early as possible [174-176]. However, the levels in the same 
colon and breast cancer patients six weeks after surgical tumor resection did not drop 
significantly. Moreover, some patients showed even higher TN-W concentration after tumor 
removal. This of course raises the question whether the TN-W detectable in the serum is 
derived from the tumor mass itself or whether its levels are influenced by any co-morbidity 
(e.g. cardiovascular diseases, inflammatory disease) or through indirect effects of the tumor 
on other organs (e.g. bone marrow, liver). Another explanation could be that TN-W is a very 
stable protein and that it is still circulating in serum six weeks after tumor removal. This 
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question could be answered by analyzing serum TN-W levels of the same patients in longer 
follow-up studies. 
 
To obtain evidence for a causal link between high TN-W serum levels and TN-W presence in 
the tumor, we investigated its expression in colon tumors by immunoblot analysis and 
immunohistochemistry. We were able to demonstrate that TN-W is highly expressed in the 
majority of colon cancer patients and that it is strictly localized to the tumor stroma, 
overlapping with TN-C expression. To really prove that the tumor mass is the source of serum 
TN-W, we would need to have serum and tissue samples from the same cancer patients. A 
clear correlation between high TN-W expression in tissue and serum would strongly support 
the concept of tumor-origin of serum TN-W.  
 
We suggest that TN-W might have the better potential to serve as tumor marker than TN-C. 
This conclusion could be drawn based on three observations: (i) the difference of mean serum 
TN-W level between diseased and healthy individuals was much more pronounced than that 
of TN-C; (ii) normal colon mucosae are negative for TN-W, while there is some expression of 
TN-C; and (iii) TN-W is not known so far to be linked to other pathological situations such as 
infection or inflammation. Such secondary expression sites for sure influence serum levels of 
a given biomarker. Why TN-W levels in breast cancer sera did not change cannot be 
explained so far. Therefore, it would be important and necessary to study more cancer types to 
evaluate the clinical significance of TN-W. Our observations warrant follow-up studies to 
evaluate the potential diagnostic or prognostic relevance of TN-W in colorectal cancer and 
possibly in other cancers types. 
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IV.4 Regulation of tenascin-C and tenascin-W 
Our extensive immunoblot studies of different tumor tissue extracts revealed that TN-W and 
TN-C amounts varied greatly between different patients. This implied that regulatory 
mechanisms exist that are unique to TN-W and such that are unique to TN-C. However, we 
cannot exclude regulatory mechanisms that have been conserved between the two tenascins. 
Several publications exist about the regulation of TN-C and its promoter sequence in several 
different species. Promoter regions from chicken, mouse, and human TN-C have been 
identified. In all these species, the proximal promoter region displayed remarkable similarities 
and several regulatory elements have been conserved [156, 177-180]. The optimal promoter 
activity of the region upstream of the TN-C transcription initiation site was found within 220 
bp, in a region containing potential binding sites for PAX, NF-1 and Sp1 [156]. Studies in 
human fibroblasts revealed that Sp1 co-operated with Ets transcription factors in TN-C 
promoter activation of PDGF-stimulated cells and also with Smad3/Smad4 in TGFβ-
stimulated cells [109, 111]. 
 
So far only little is known about the regulation of TN-W. The only known fact is the 
observation that TN-W can be induced by TNFα and/or BMP2 in MEFs, C2C12, and in 4T1 
mouse breast cancer cells [56, 151]. Unfortunately, we did not succeed in repeating such 
experiments in different human cell lines. 
 
To characterize the human TN-W promoter region, we performed 5’RACE and identified a 
non-coding first exon, which is located 9.48 kb upstream of the ATG-containing exon. This 
feature is common within the TN-W gene family. In contrast to the TN-C promoter region, the 
TN-W promoter does not contain any obvious promoter motifs such as CpG islands or a 
TATA box.  By means of luciferase reporter constructs we identified the optimal TN-W 
promoter activity within the 250 bp upstream of the transcription initiation site. It would be 
interesting to use TN-W and TN-C promoter constructs to dissect their responsiveness to 
different growth factors or other stimuli. With this approach we could try to find common or 
specific stimuli for the two tenascins. Furthermore, we could identify the promoter sequences 
for the specific responses and link them to the involvement of particular transcription factors. 
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Results of such studies might explain the prominent expression of TN-W in tumors. Since we 
could not find a good cell line for TN-W induction, we did not apply this approach so far with 
human constructs. Maybe it would be easier to switch to the mouse TN-W promoter, since 
there, we have cell lines (C2C12, MEFs, 4T1) in which endogenous TN-W can be induced. 
Therefore, we know that in these cells all factors needed for TN-W expression are present. 
 
For TN-C we discovered a complete novel signaling pathway that leads to induction of TN-C: 
the Notch2 signaling pathway. By aligning the sequences located upstream of the 
transcription initiation sites of the established human and murine Notch2 target genes HES1 
(hairy/enhancer of split) and HES5 [181] with the TN-C promoter sequence, two conserved 
motifs were identified: the TATA box at -30 bp, and a RBPJk binding motif GTGGGAA at -
80 bp. The striking conservation in sequence and position of the latter element prompted us to 
consider a functional RBPJk-responsive element in the TN-C promoter. Indeed, by luciferase 
reporter assays we could establish a molecular connection between Notch2/RBPJk signaling 
and TN-C expression.  
 
Notch proteins can either act as oncogenes or as tumor suppressor genes [182] depending on 
the cellular context. We found Notch2 gene amplification together with elevated protein levels 
in half of the glioblastoma (GBM) cell lines tested and identified TN-C as a Notch2 target 
gene. GBMs belong to the most aggressive human cancers [183, 184]. Their highly invasive, 
proliferative and angiogenic properties might be partly explained by the up-regulation of TN-
C, which is known to be involved in these aspects of tumorigenesis (for reviews see [95, 
100]). From a clinical point of view, the identification of the Notch2 pathway as novel 
oncogenic signaling event in gliomagenesis allows the development of new therapeutic 
approaches to interfere with cancer progression by targeting this pathway. For instance 
gamma-secretase inhibitors that impair Notch receptor processing, and therefore diminish 
sensitivity to ligand-induced signaling are promising drugs. They may be considered as 
potential anti-cancer drugs for Notch2-positive gliomas.  
 
The connection between Notch2 and TN-C is not only interesting in the context of 
gliomagenesis, but also in the context of development. Normal brain development includes 
the action of Notch2 which is expressed in ventricular germinal zones [185, 186]. Notch 
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maintains proliferation and prevents differentiation of neuron precursors as well as of 
immature glial cells. Conversely, TN-C deficient mice show defects in proliferation and 
migration of neuronal precursors [133, 134]. This suggests that during normal brain 
development, the Notch2/RBPJk/TN-C signaling cascade could be responsible, at least in 
part, for maintaining the reservoir of neuronal precursor cells. This would also be in 
agreement with our findings that Notch2 and TN-C are more prominently expressed in the 
undifferentiated GBMs compared to well-differentiated oligodendrogliomas (OG) in which 
only a subset were moderately positive for TN-C [187].      
 
The Notch2 locus is located on chromosome arm 1p. This locus does not include the TN-C 
gene, which is found on chromosome 9. Thus, high TN-C expression associated with high 
Notch2 levels cannot be simply explained by amplification of the Notch2 locus including the 
TN-C gene. However, the genes coding for TN-W and TN-R are adjacent to the Notch2 gene 
[57]. Therefore, amplification of the Notch2 locus could eventually lead to up-regulation of 
TN-W or TN-R. It would be of high interest to test whether Notch2 positive gliomas are also 
positive for TN-W or TN-R.  
 
Our experiments have only addressed TN-C induction by Notch2. What about Notch1 which 
is also implicated in tumorigenesis and in important developmental decisions [188]? Since 
Notch1 signaling involves the same canonical signal cascade as Notch2, it will be reasonable 
to consider in the future whether TN-C can be regulated by Notch1 as well. 
 
To summarize, we propose a novel pathway, the Notch2/RBPJk/TN-C cascade, which plays a 
critical role in gliomagenesis. Induction of TN-C might lead to enhanced tumor cell motility 
which is a hallmark of GBMs.  
 
Moreover, we analyzed TN-C expression in primary human lung fibroblasts derived from 
asthmatic patients. Asthma is characterized by chronic airway inflammation and ECM 
remodeling. Under physiological conditions tissue homeostasis is maintained by the 
equilibrium between ECM synthesis and degradation. In asthma patients, however, this 
equilibrium is altered leading to structural changes. Fibroblasts belong to the main producer 
of ECM, and TGF-β is the most potent ECM inducing factor in vitro. Since ECM is important 
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for many cellular aspects, alterations in its composition and amount produced may influence 
and prolong the inflammatory and remodeling processes. Current therapies for asthma include 
inhalation of corticosteroids and long acting β2-agonists (LABA), but their effects on ECM 
remain only poorly understood. Here we have analyzed the effect of corticosteroids and 
LABA on the expression levels of TN-C and fibronectin using primary human lung 
fibroblasts. Corticosteroid treatment negatively regulated expression of TN-C. This is in 
agreement with previous reports [189]. The response of fibronectin to corticosteroids was 
exactly the opposite: corticosteroids increased fibronectin deposition. LABAs neither showed 
a prominent effect on TN-C or fibronectin expression nor modulated the effect of 
corticosteroids. Therefore, our findings might have implications for the short- and long-term 
treatment strategies in regard to airway remodeling in asthma and COPD.  
IV.5 Perspectives 
In recent years, it has become evident that tumors require a congenial microenvironment for 
progression and that carcinogenesis is accompanied by several stromal changes. This finally 
leads to an aberrant microenvironment that facilitates tumor growth and invasion. TN-C is 
known to be de novo expressed in the tumor stroma by activated fibroblasts [19]. Our studies 
in human mammary and colon tumors showed now the induction of a second tenascin family 
member, TN-W in the activated tumor stroma and identified TN-W as a novel marker for 
tumor stroma. Whether its presence directly promotes cancer progression needs to be further 
investigated.  
 
Although several lines of evidence have emphasized a role for TN-C and TN-W in breast and 
in other tumors [9], their real function(s) may still be missing. 2-dimensional (2-D) in vitro 
systems have generated a first large amount of information about different aspects of tenascin 
function. However, it seems that tenascin research has reached a limit for new information 
with these 2-D studies. To gain more details about the real in vivo function of tenascins, we 
have to go a step further with our biological studies. In particular, we have to take into 
account that TN-C as well as TN-W expression may depend on epithelial-mesenchymal 
interactions. These conditions cannot be imitated in 2-D culture systems. There is a definite 
need for more appropriate 3-D models which mimic the in vivo situation as adequately as 
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possible and which can drastically change cancer cell behavior [190, 191]. With such systems, 
we can (re-)study the influence of TN-W and TN-C on complex processes such as cell 
adhesion, proliferation, and migration. 
 
Another straight forward approach to elucidate tenascin function would be the generation of 
knock-out and knock-in mice. TN-C-deficient mice already exist for some time [167, 192]. 
However, they did not show any severe phenotypes [96]. The knock-out mouse published in 
1992 [167] was among the first to be made by homologous recombination. Nowadays, new 
knock-out strategies (flox/cre system) allow the generation of conditional knock-outs, which 
are based on tissue-specific inactivation of the gene of interest. Probably this would be the 
appropriate system to study tenascin function in different tissues and at different 
developmental stages of an organism. Concerning TN-W, no knock-out mice exist so far. TN-
W-deficient mice most likely would not show any severe phenotypes. However, they would 
be the prerequisite for the generation of the TN-C/TN-W double knock-out mice. These mice 
could then be analyzed for tumor development and tumor progression in various cancer 
aspects such as angiogenesis, metastasis, invasion, proliferation and cancer stem cell biology.     
 
Tenascin researchers have hoped that deletion of the TN-C gene would produce more than just 
subtle phenotypes. However, a simple explanation for the lack of strong functional defects in 
these mice could be the compensatory expression by other molecules. The newly described 
TN-W could be an interesting and promising candidate for this compensatory function. 
During development and in tumors, TN-W shows very similar expression patterns to TN-C 
[56, 151, 169]. Therefore, we can hypothesize that at least in some specific tissues, TN-W 
could compensate for the lack of TN-C thereby hiding the real defects in TN-C-deficient 
mice. 
 
TN-W is specifically expressed in the tumor stroma and may represent a good anti-tumor 
target. A possible application for TN-W would be the use of specific monoclonal antibodies 
which are coupled to bioactive molecules to deliver drugs specifically to the tumor mass 
[193]. This method is already applied using TN-C-coupled antibodies (see “Introduction”) to 
treat glioma and lymphoma patients [137-139]. However, we showed here that TN-W is even 
more exclusively expressed in tumor tissue than TN-C, with (so far) no expression in any 
DISCUSSION 
 
179 
 
healthy tissues tested. This implies that antibodies specifically recognizing TN-W have great 
potential to localize to the tumor mass or to deliver chemotherapeutic reagents very precisely 
to the tumor site.  If we cannot find or interfere with TN-W functions in the context of tumor 
progression, its prominent presence in tumors could be beneficial for patients in context of 
tumor prevention or treatment. 
 
Here, we have presented the very first descriptions of human TN-W. Our data put forward 
TN-W as a marker for transformation of the normal physiological stroma to an activated 
stroma in breast and in colon cancer. Furthermore, we show that TN-W can influence cancer 
and stromal cell behavior. These data are novel and we are convinced that they will serve as 
the basis for many future studies on TN-W and its role in cancer. 
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V. Appendix  
V.1 Experimental procedures (unpublished data) 
Luciferase constructs 
 
Tenascin-W and tenascin-C promoter constructs were amplified by the Expand High Fidelity 
PCR System (Roche), using HEK293 genomic DNA as template. The primer sequences used 
for the nested PCR reactions are listed in table V.I and table V.II. The reverse primer2 (rev2) 
and the forward primers2 for the second reactions included NheI and XhoI restriction sites, 
respectively, enabling directional cloning into the pGL3-basic vector (Promega). 
 
Table V.I: Sequences of the primers used for the TNW luciferase constructs 
 
 
 
 
 
 
 
 
 
 
 
First PCR reactions were performed with the primers labeled with 1, second 
PCR reactions with the primers labeled with 2. 
 
Table V.II: Sequences of the primers used for the TNC luciferase constructs 
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5’RACE 
 
To characterize the 5’ end of human TN-W mRNA sequence, the 5’ / 3’ RACE Kit, 2nd 
Generation (Roche) was used according to the manufacturer’s instructions. The primer 
sequences used for the 5’RACE are listed in table V.III. Primer sets for the second PCR 
reaction included NotI and SalI restriction sites, respectively. Total RNA was isolated from 
KRIB cells using Trizol (Invitrogen). cDNA was synthesized using the human tenascin-W 
specific primer hSP1. To identify the 5’ end of the TN-W mRNA two gene specific primers 
(hSP2 and hSP3) were used. cDNA quality was tested by two control primers. The resulting 
PCR fragments were ligated into the pBluescript KS vector (Stratagene) and sequenced. 
 
Table V.III: Sequences of the primers used for the 5’ RACE 
 
 
 
 
 
Luciferase assay  
 
HT1080 (ATCC # CCL-121) and Saos2 cells (ATCC # HTB-85) were plated in 6-well dishes 
at a density of 80000 cells/well in the presence of 1%FCS. The next day at a cell-confluency 
of about 60-70 %, they were transfected with the luciferase constructs by FuGENE (Roche) 
and incubated for another 24 hours. Thereafter, cells were washed twice with PBS and lysed 
in 100 μl of 1x Reporter Lysis Buffer (Promega). The cell lysates were incubated on ice for 
30 minutes, centrifuged and diluted in lysis buffer in serial dilutions (1/5, 1/10, 1/100). 50 μl 
of each sample was put into a 96 well Microlite 1 Flat Bottom Microtiter Plate (Catalys), and 
luciferase activity was measured in a Mithras LB 940 spectrometer (Berthold Technologies). 
To normalize the transfection efficiency, a β-galctosidase construct was co-transfected. From 
the cell lysates described above, 1/2, 1/5, and 1/10 dilutions were made and 50 μl of each 
sample were transferred into a 96 well Test Plate (TPP). Afterwards, 50 μl of the β-
galactosidase substrate was added into each well and after incubating the plate for 30 minutes 
at 37ºC, the reaction was stopped by adding 150 μl of 1M Na2CO3-. Plates were read with a 
VERSAMAX Microplate reader (Molecular Devices) at 490 nm against 620 nm. 
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Buffers and solutions used for Luciferase assays 
 
1 M Na2CO3-  stop solution 
 
10xGlycin Buffer: 150 mM MgSO4 
     250 mM Glycin 
     pH 7.8 
 
10xLuciferin:  2 mM in 1x glycin buffer 
     Sterile filtered 
     Stored at -20ºC 
 
ATP:   100 mM in H2O, pH 7.8 
     Stored at -20ºC 
 
β-Gal substrate (2x): 0.2 M Na-phosphate buffer, pH 7.5 
     2 mM MgCl2 
     5.5 mM ONPG     
     0.1 mM β-mercaptoethanol 
     Stored at -20ºC 
 
Luciferase substrate: 10x glycin buffer 150 μl 
(for 1 ml)  Luciferin (10x) 150 μl 
ATP     75 μl 
H2O   625 μl 
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V.2 List of Abbreviations 
BM basement membrane 
BMP2 bone morphogenetic protein 2 
bp base pairs 
BSA bovine serum albumin 
CAF cancer-associated fibroblast 
CAH congenital adrenal hyperplasia 
CEA carcinoembryonic antigen 
CNS central nervous system 
Col collagen 
COPD chronic pulmonary disease 
CRP C-reactive protein 
DKK1 dickkopf 1 
DNA deoxyribonucleic acid 
ECM extracellular matrix 
EDS Ehlers-Danlos syndrome 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent  
 assay 
EMT epithelial-mesenchymal transition 
EPC endothelial precursor cell 
ERK extracellular signal-related kinase 
FAK focal adhesion kinase 
FCS fetal calf serum 
FGF fibroblast growth factor 
FN III  fibronectin type III 
FN fibronectin 
FSP1 fibroblast specific protein 1 
GAG glycosaminoglycan 
GBM glioblastoma 
HES hairy/enhancer of split 
HGF hepatocyte growth factor 
ILP isolated limb perfusion 
IP immunoprecipitation 
LABA long-acting β2-agonists 
MAPK mitogen-activated protein kinase 
MMP matrix metalloproteinase 
mRNA messenger RNA 
OG oligodendroglioma 
PBS phosphate-buffered saline 
PDGF platelet-derived growth factor 
RACE rapid amplification of cDNA ends 
RNA ribonucleic acid 
ROS reactive oxygen species 
RTPCR real-time polymerase chain reaction 
SDF1 stromal-derived growth factor 
SDS sodium dodecyl sulfate 
SPARC secreted protein acidic and rich in 
cysteine 
TBS Tris-buffered saline 
TGFβ transforming growth factor β 
TM1 tropomyosin 1 
TN-C tenascin-C 
TNFα tumor necrosis factor α 
TN-R tenascin-R 
TN-W tenascin-W 
TN-X tenascin-X 
VEGF vascular endothelial growth factor 
Wnt wingless/int 
β-Gal β-galactosidase
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